REVIEW article

Front. Cell. Infect. Microbiol., 24 July 2026

Sec. Intestinal Microbiome

Volume 16 - 2026 | https://doi.org/10.3389/fcimb.2026.1815265

Infection-driven gut dysbiosis and epigenetic programming of microglia: toward a systems level framework linking microbial metabolites, neuroinflammation, synaptic dysfunction, and probiotic modulation

  • School of Bioengineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, Shandong, China

Abstract

Neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases are increasingly viewed as conditions influenced by systemic immune and metabolic disturbances beyond the central nervous system (CNS). Emerging evidence suggests that infection-driven intestinal dysbiosis may function as an upstream contributor to systemic inflammation through disruption of gut barrier integrity. Increased permeability can facilitate the translocation of microbial components and metabolites into circulation, potentially influencing host immune programming via epigenetic mechanisms. Among CNS immune cells, microglia appear particularly susceptible to such peripheral cues due to their longevity and capacity for stimulus-dependent transcriptional adaptation. Experimental studies indicate that transient systemic immune challenges may induce persistent chromatin-level alterations within microglial regulatory regions, thereby reshaping their responsiveness to subsequent inflammatory stimuli or age-related stressors, including oxidative stress, chronic low-grade inflammation (inflammaging), and age-associated decline in cellular homeostatic and repair mechanisms. This phenomenon, often described as innate immune memory, may contribute to sustained neuroinflammatory activity and impaired synaptic function across the lifespan. Microbiota-derived metabolites, including short-chain fatty acids and tryptophan catabolites, have been implicated in modulating host transcriptional pathways through histone deacetylase inhibition and receptor-mediated signaling.

1 Introduction

Neurodegenerative disorders (NDDs) represent one of the most pressing biomedical challenges of the twenty-first century, not only because of their rising prevalence but also due to their striking heterogeneity in onset, progression, and clinical expression. Individuals exposed to seemingly similar genetic risks and environmental influences often follow markedly different neurocognitive trajectories. This variability suggests that disease vulnerability may be shaped by modulatory systems operating beyond classical protein aggregation paradigms (Fernández‐Ruiz, 2019; Martinelli et al., 2019). Increasingly, attention has shifted toward systemic and environmental contributors that influence how the central nervous system (CNS) responds to stress across the lifespan. Among these, peripheral immune perturbations and intestinal ecosystem dynamics have emerged as important determinants of neuroinflammatory tone (Cannon and Greenamyre, 2011). The gut–brain axis has reshaped contemporary understanding of brain–body communication. The brain is no longer viewed as an isolated organ. Instead, it operates within a bidirectional network involving immune mediators, metabolic intermediates, microbial metabolites, and neural circuits. The intestinal microbiota represents a dynamic ecological system that can influence host physiology far beyond digestion (Rutsch et al., 2020). Early research in this field mainly focused on compositional differences in microbial taxa associated with neurological disease. However, a more functional perspective is now emerging. This perspective emphasizes regulatory and metabolic interactions rather than taxonomy alone (Vanuytsel et al., 2023). In parallel with advances in microbiome research, the concept of immune programming has gained importance. Peripheral inflammatory events, whether triggered by infection, barrier dysfunction, or systemic immune activation, may not only generate transient cytokine responses. Instead, evidence suggests that these events can recalibrate immune responsiveness even after the initial stimulus has resolved. This recalibration may occur through mechanisms that alter transcriptional accessibility, reshape signaling thresholds, or modify the balance between pro- and anti-inflammatory pathways (Ilott et al., 2016). Within this framework, the key question is no longer whether peripheral inflammation affects the brain. Instead, it is whether repeated or unresolved immune perturbations can establish durable neuroimmune set-points that influence vulnerability to later-life pathology.

One potential mediator of these long-term effects is epigenetic regulation. Chromatin architecture provides a biologically plausible mechanism through which environmental signals can be encoded without changing DNA sequence. Modifications in histone acetylation, methylation, and enhancer accessibility allow cells to adjust gene expression in response to external stimuli (Gräff et al., 2011; Mazzio and Soliman, 2012). Importantly, these regulatory layers are dynamic but also capable of persistence. This allows prior exposures to shape future cellular responses. In immune cells, including tissue-resident macrophages, chromatin remodeling has been linked to innate immune memory. This memory can bias subsequent inflammatory responses. Whether similar mechanisms operate in infection-associated microbial disturbances and neurodegenerative susceptibility remains an open question (Schultze, 2017; Zhang and Cao, 2021). Microglia are long-lived resident immune cells of the CNS. They continuously survey the brain microenvironment. They also integrate signals from systemic circulation, metabolic status, and neuronal activity. Experimental studies show that peripheral immune challenges can alter microglial inflammatory thresholds and cytokine responses later in life (Bilbo et al., 2006; Godbout et al., 2008). These findings suggest that microglial priming may represent a cumulative record of peripheral immune history. Microglia may therefore not act only as passive responders to neuronal pathology. Instead, they may actively shape neurodegenerative trajectories through state-dependent inflammatory regulation.

At the level of the intestinal ecosystem, systemic infection has been associated with reproducible changes in microbial balance and barrier integrity. These changes can increase exposure to microbial-derived products (Yeoh et al., 2021). Such peripheral disturbances suggest that infection-driven dysbiosis may influence regulatory networks beyond the gut. Moreover, microbial metabolites, including short-chain fatty acids (SCFAs) and tryptophan-derived compounds, can interact with chromatin-modifying enzymes and transcriptional regulators under defined experimental conditions (Chang et al., 2014; Tan et al., 2022). Most mechanistic evidence comes from peripheral tissues. However, these findings suggest that microbiota-derived signals may intersect with host epigenetic systems that regulate immune responsiveness across tissues and time. Preclinical models of neurodegeneration have also investigated whether targeted modulation of microbial communities can influence synaptic resilience and inflammatory signaling (Asl et al., 2019; Li et al., 2022). Although these findings are context-dependent and require careful interpretation, they suggest that microbiota–immune–brain interactions are not merely correlative. Instead, they may represent modifiable axes within complex disease networks. Importantly, such interventions can affect not only inflammatory mediators but also molecular pathways related to synaptic stability and cellular stress responses. This highlights the interconnected nature of immune and neuronal regulation (Fung et al., 2017; Cryan et al., 2019). Despite these advances, a fully integrated framework linking infection-associated dysbiosis, epigenetically mediated immune programming, and microglial responsiveness across the lifespan has not yet been systematically established. Most existing studies examine individual components, such as microbiome alterations, epigenetic regulation, synaptic dysfunction, or neuroinflammation, in isolation. The central premise of this review is that these domains may converge within a shared regulatory architecture. In this model, peripheral immune perturbations—particularly those associated with infection and barrier dysfunction—interact with chromatin-level mechanisms. Together, these interactions shape long-term neuroimmune trajectories (Miro-Blanch and Yanes, 2019; Morais et al., 2021). Accordingly, this review synthesizes evidence from experimental and translational research to explore how infection-driven intestinal disturbances may interact with host epigenetic machinery and influence microglial programming (i.e., long-term functional and transcriptional adaptation of microglia in response to environmental or immune stimuli), synaptic vulnerability (i.e., increased susceptibility of synapses to dysfunction or loss under inflammatory or stress conditions), and neuroinflammatory outcomes. By integrating insights from microbial ecology, immune biology, and chromatin regulation, the aim is to outline a systems-level perspective that extends beyond descriptive associations toward mechanistic plausibility. Although causal relationships remain to be fully established, clarifying how peripheral environmental exposures shape central immune states may represent an important step toward identifying modifiable determinants of neurodegenerative susceptibility. Importantly, previous research has often examined microbiome alterations in neurodegeneration, epigenetic regulation of immune responses, and microglial priming largely in isolation. The present review therefore advances a conceptual synthesis in which infection-associated intestinal dysbiosis and epithelial barrier perturbation are viewed not merely as correlates of systemic inflammation, but as potential upstream modulators of chromatin-level immune programming with implications for long-term neuroinflammatory set-points. This integrative framework aims to clarify how peripheral immune perturbations may contribute to variability in neurodegenerative vulnerability while maintaining a cautious distinction between biologically plausible mechanisms and established causality.

2 Microbiota–gut–brain communication in neurological homeostasis: neural signaling, microbial metabolites, and dysbiosis-driven neurodegeneration

The gut–brain axis is a complex, bidirectional communication system that connects the gastrointestinal tract and the CNS through neural, hormonal, metabolic, and immune pathways. It plays a critical role in maintaining neurological homeostasis and is increasingly recognized for its involvement in major NDDs, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) (Caradonna et al., 2024). Key players in this interaction include the vagus nerve, the hypothalamic–pituitary–adrenal axis (HPA), the immune system, and microbial-derived metabolites such as SCFAs, neurotransmitters, and lipopolysaccharide (LPS) (Forsythe et al., 2014; Carlessi et al., 2021; Rusch et al., 2023). The vagus nerve, the tenth cranial nerve, is a central component of the gut–brain axis and serves as a primary channel for neural signals from the gut to the brain. It connects the enteric nervous system with the brainstem and can transmit information in both directions (Chuyue et al., 2020). Evidence suggests that alpha-synuclein, a misfolded protein associated with PD, may propagate along this route from the gut to the brain. Enteroendocrine cells (EECs), which possess neuron-like properties and express alpha-synuclein, form direct synaptic connections with enteric neurons. These neuropod-containing cells are capable of sensing dietary and microbial signals and relaying them via synaptic-like processes, providing a direct neuroepithelial interface between the gut lumen and the nervous system (Chandra et al., 2017). Microbial metabolites further modulate this communication network. SCFAs, particularly butyrate, propionate, and acetate, are produced by bacterial fermentation of dietary fibers (Kaur et al., 2025).

These molecules influence various aspects of host physiology, including immune regulation, gut barrier integrity, and brain function. SCFAs can cross the blood–brain barrier, where they interact with microglia, modulating neuroinflammatory responses and promoting neuronal homeostasis. They also influence the differentiation of regulatory T cells and stimulate the release of gut hormones via EECs, reinforcing gut–brain communication (Haase et al., 2020; Filippone, 2021). Conversely, gut dysbiosis—an imbalance in microbial composition—has been implicated in the pathophysiology of both AD and PD. In PD, a significant reduction in SCFA-producing bacteria such as Faecalibacterium and Prevotella is often reported, accompanied by an increase in pro-inflammatory taxa like Enterobacteriaceae. These alterations are associated with increased intestinal permeability, also known as “leaky gut,” allowing LPS and other microbial products to enter the systemic circulation. This triggers widespread inflammation, disrupts the blood–brain barrier (BBB), and promotes alpha-synuclein aggregation in the brain, contributing to dopaminergic neuron degeneration (Petrov et al., 2017; Drago et al., 2019; Pietrucci et al., 2019). Similar patterns of dysbiosis have been observed in AD. Patients with AD show lower levels of beneficial bacteria and higher proportions of pro-inflammatory species. This microbial imbalance correlates with increased levels of LPS and bacterial amyloids in the gut, which may activate immune responses and promote amyloid-beta (Aβ) aggregation in the brain. Certain gut bacteria, including Escherichia coli and Salmonella, produce curli-type amyloid fibers capable of inducing cross-seeding of misfolded proteins such as Aβ and tau. These bacterial amyloids can be internalized by enteric neurons and potentially travel to the CNS, promoting the formation of amyloid plaques and neurofibrillary tangles (Aboytes Flores, 2023; Ali et al., 2023). Studies in animal models support the idea that gut microbiota influence brain pathology. Germ-free transgenic mice show reduced Aβ deposition, which increases upon colonization with microbiota from AD mice. Similarly, rodents exposed to curli-producing E. coli strains exhibit elevated brain alpha-synuclein levels and increased neuroinflammation compared to controls. These findings suggest that microbial factors contribute to protein aggregation pathways central to NDDs (Levi et al., 2003; Harach et al., 2017; Sampson et al., 2020). Beyond neural signaling, gut microbes also impact neuroendocrine functions. Bacterial metabolites influence the HPA axis, which regulates stress responses and hormonal secretion. Microbes also produce neuroactive compounds such as serotonin, γ-aminobutyric acid (GABA), and dopamine, which can affect behavior, memory, and synaptic plasticity (Farzi et al., 2018; Xu et al., 2024).

3 Epigenetic regulation in neurodegeneration: DNA methylation, histone modifications, and miRNA networks in AD and PD

Epigenetic mechanisms play a crucial role in regulating gene expression without altering the underlying DNA sequence. These mechanisms include DNA methylation, histone modifications, and non-coding RNAs, all of which are central to brain development, cognitive function, and the pathogenesis of NDDs (Jakovcevski and Akbarian, 2012). During aging, disruptions in these regulatory systems can contribute to conditions such as AD and PD (Mastroeni et al., 2011). DNA methylation involves the addition of a methyl group to the cytosine base in CpG dinucleotides, a process governed by DNA methyltransferases. This modification can silence genes or reduce their expression and is essential for maintaining cellular identity and genomic stability (Xu et al., 2019; He et al., 2021). In the nervous system, DNA methylation is highly dynamic and responsive to environmental stimuli. Neuronal activity has been shown to induce methylation changes, influencing synaptic plasticity and memory consolidation. For example, alterations in methylation patterns have been observed in genes associated with long-term potentiation, a process critical for learning (Yu et al., 2011; Halder et al., 2016). Age-associated epigenetic drift and methylation instability have been linked to progressive neuronal vulnerability and neurodegenerative susceptibility (Berni Canani et al., 2012; Stein and Riber, 2023). Histone modifications—such as methylation, acetylation, phosphorylation, and ubiquitination—alter chromatin structure and gene accessibility. These modifications are catalyzed by specific enzymes (e.g., histone acetyltransferases and deacetylases) and regulate transcriptional activity in neurons. Studies have demonstrated that learning-related experiences trigger specific histone changes in hippocampal neurons, including increased acetylation at histone H3 and H4 sites. Chromatin immunoprecipitation sequencing studies in microglia have revealed enrichment of active histone marks such as H3K27ac and H3K9ac at promoters of inflammatory genes during neuroinflammatory activation, suggesting epigenetic priming of immune responses.

Assay for Transposase-Accessible Chromatin sequencing further demonstrates increased chromatin accessibility in LPS-stimulated microglia, particularly in enhancer regions associated with NF-κB signaling, highlighting dynamic epigenetic remodeling during inflammation. Non-coding RNAs, particularly miRNAs, further expand epigenetic regulatory complexity. These small RNA molecules (18–25 nucleotides) bind to complementary sequences on target mRNAs, resulting in translational repression or degradation. Some miRNAs are themselves regulated by DNA methylation and histone modifications, forming feedback loops with epigenetic machinery. In turn, miRNAs regulate key epigenetic enzymes, establishing tightly controlled gene regulatory networks (Hombach and Kretz, 2016; Bure et al., 2022). Dysregulation of miRNAs has been widely implicated in neurodegeneration. In AD, altered levels of miR-34a, miR-124, and miR-9 have been linked to Aβ accumulation, tau phosphorylation, and neuroinflammation (Du et al., 2017; Lee et al., 2021). Similarly, in PD, miR-155, let-7a, and miR-222 are associated with dopaminergic neuronal loss and inflammation (Vallelunga et al., 2014; Elangovan et al., 2023). Emerging evidence highlights a strong interaction between the gut microbiota and host epigenome in aging and neurodegeneration (Xu et al., 2019). Gut microbes produce metabolites—especially SCFAs such as butyrate, acetate, and propionate—that cross the BBB and regulate epigenetic mechanisms in neural tissue. Butyrate acts as a histone deacetylase (HDAC) inhibitor, promoting histone acetylation and enhancing transcription of anti-inflammatory and neuroprotective genes (Berni Canani et al., 2012; Stein and Riber, 2023). Moreover, LPS derived from Gram-negative bacteria activates innate immune signaling via Toll-Like Receptor 4 (TLR4)/Nuclear Factor kappa B (NF-κB) pathways and induces epigenetic remodeling. LPS exposure has been associated with alterations in DNA methylation and histone modification patterns, leading to persistent inflammatory gene activation in neural and immune cells (Zhang and Ghosh, 2000a; Yang et al., 2021; Liu et al., 2022). Importantly, these microbial–epigenetic interactions extend to non-coding RNA regulation. LPS-induced signaling has been shown to upregulate pro-inflammatory miRNAs such as miR-34a, miR-146a, and miR-155, which target neuroprotective genes including NF-L, thereby contributing to axonal injury and synaptic dysfunction in AD (Liu et al., 2022). Furthermore, LPS-triggered NF-κB activation promotes transcriptional reprogramming of immune cells through miRNA-mediated feedback loops, reinforcing chronic neuroinflammatory states (Zhang and Ghosh, 2000b). In parallel, circulating exosomal miRNAs have been shown to correlate with gut microbial composition and cognitive decline in AD, supporting a microbiota–gut–brain axis in which microbial dysbiosis is linked to systemic miRNA signatures involved in disease progression (Gui et al., 2015; Lin et al., 2025). These miRNAs regulate genes involved in synaptic transmission, neurotrophin signaling, and cellular stress responses, suggesting a functional bridge between microbiota and neuronal gene regulation (Issler and Chen, 2015). Similarly, altered expression of inflammation-related microRNAs, including miR-155 and miR-146a, has been associated with dopaminergic neuronal loss and activation of neuroinflammatory signaling pathways in PD models, further supporting a microbiota–immune–miRNA regulatory axis in neurodegeneration (Gui et al., 2015; Yang et al., 2021).

4 Microbiota-derived SCFAs as epigenetic modulators of neuroinflammation

Recent discoveries linking the gut microbiome to neurological health have highlighted the role of microbial metabolites, particularly SCFAs, in gut–brain communication and neuroimmune regulation. SCFAs—mainly acetate, propionate, and butyrate—are produced in the colon through bacterial fermentation of dietary fiber and serve as key biochemical mediators connecting intestinal dysbiosis with host physiological and epigenetic responses. Importantly, in the context of infection-associated dysbiosis, SCFA production is often reduced, leading to a shift from anti-inflammatory to pro-inflammatory signaling states that may contribute to systemic immune activation and neuroinflammation. Among their many functions, SCFAs influence gene expression in the CNS by modulating epigenetic mechanisms, including HDAC inhibition and regulation of DNA methylation (Dong and Cui, 2022; Song et al., 2022). These effects collectively contribute to the regulation of immune responses, neuronal plasticity, and cognitive function, particularly during aging and NDDs. Butyrate is the most extensively studied SCFA due to its potent HDAC inhibitory activity. HDACs remove acetyl groups from histone proteins, resulting in chromatin condensation and transcriptional repression (Khan and Jena, 2015). By inhibiting HDAC activity, butyrate promotes chromatin relaxation and facilitates transcription of genes involved in anti-inflammatory and neuroprotective pathways (Patnala et al., 2017). Mechanistically, this epigenetic modulation is particularly relevant in microglia, where chromatin accessibility determines the magnitude of inflammatory gene expression in response to peripheral immune signals.

In primary microglial cultures, butyrate has been shown to suppress NF-κB activation, a central transcription factor in inflammatory signaling. This results in reduced expression of pro-inflammatory cytokines such as iInterleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), demonstrating a direct link between SCFA-mediated epigenetic regulation and neuroinflammatory suppression (Sun et al., 2025) (Figure 1). Experimental studies using LPS to stimulate inflammation in microglial cells and hippocampal slice cultures have demonstrated the anti-inflammatory effects of sodium butyrate. Pretreatment with butyrate attenuated the production of nitric oxide and inflammatory cytokines in response to LPS (Huuskonen et al., 2004). This suggests that SCFAs not only regulate baseline epigenetic states but also reshape stimulus-dependent inflammatory responsiveness, consistent with the concept of epigenetically mediated immune priming. Interestingly, in immortalized microglial cell lines, butyrate and other SCFAs such as propionate and valerate have been reported to enhance inflammatory responses under certain conditions (Wang et al., 2017; Xiao et al., 2018). SCFAs also play a significant role in brain aging and neuroimmune regulation. With aging, systemic inflammation increases and is accompanied by microglial overactivation and increased vulnerability to immune challenges. In aged animal models, dietary fiber supplementation (e.g., inulin) increases colonic SCFA production, particularly butyrate, and is associated with reduced peripheral inflammation and a shift in microglial gene expression toward an anti-inflammatory phenotype (Muthyala et al., 2022; Hutchinson et al., 2023). These findings support a mechanistic continuum in which dietary modulation of gut microbiota influences SCFA availability, which in turn regulates microglial transcriptional programs and neuroinflammatory tone.

Figure 1

In addition to butyrate, acetate also exerts important effects on brain function. Acetate crosses the BBB and is taken up by brain regions such as the hypothalamus, where it contributes to energy metabolism and regulation of neuropeptides involved in appetite control. It also influences acetyl-CoA availability, thereby indirectly modulating histone acetylation status in neural and glial cells (Deelchand et al., 2009; Hasegawa et al., 2012). Thus, both butyrate and acetate function as metabolic–epigenetic coupling molecules linking gut microbial activity to CNS transcriptional regulation. Beyond metabolic regulation, SCFAs also influence BBB integrity. SCFA supplementation has been shown to attenuate stress-induced behavioral deficits and restore barrier integrity without major changes in microbial composition or receptor expression (Li et al., 2016; Yan et al., 2022). This suggests that SCFAs act primarily through intracellular signaling and epigenetic regulation rather than receptor abundance changes, reinforcing their role as transcriptional modulators rather than classical ligands. Further supporting their neuroprotective role, sodium butyrate has demonstrated efficacy in cerebral ischemia-reperfusion models, improving neurological outcomes and preserving brain structure following injury (Sun et al., 2015; Mirzaei et al., 2022). These effects are associated with reduced oxidative stress, decreased pro-inflammatory cytokine production (IL-1β, IL-8, TNF-α), and reduced neuronal apoptosis. At the molecular level, butyrate modulates apoptosis-related proteins by decreasing Bax expression and increasing Bcl-2, phosphorylated Akt, and brain-derived neurotrophic factor (BDNF), suggesting activation of survival pathways such as PI3K/Akt signaling. Collectively, these effects indicate that SCFAs exert multimodal neuroprotection through integrated epigenetic, anti-inflammatory, antioxidant, and pro-survival mechanisms. Moreover, there is increasing recognition that SCFAs can influence behavior and cognition, possibly by altering gene expression patterns through their epigenetic actions (Stilling et al., 2016). In stress models, SCFA supplementation partially reversed deficits in reward-seeking behavior and reduced intestinal permeability without significantly affecting body weight, fecal SCFA content, or expression of SCFA receptors (FFAR2 and FFAR3) (van de Wouw et al., 2018). At a systems level, emerging evidence suggests that SCFAs act as epigenetic signaling intermediates that translate environmental inputs such as diet, stress, and microbiota composition into chromatin-level regulation of gene expression in the brain (He et al., 2020; Zhang et al., 2021; Nshanian et al., 2025). In conclusion, SCFAs—particularly butyrate and acetate—function as central epigenetic mediators linking gut microbial dysbiosis to neuroinflammation. Through HDAC inhibition, NF-κB modulation, and regulation of microglial transcriptional states, they provide a mechanistic bridge between peripheral metabolic signals and CNS immune regulation. Targeting SCFA pathways may therefore represent a promising strategy for modulating neuroinflammatory and neurodegenerative processes.

5 Probiotic regulation of synaptic plasticity in PD: mechanisms at the gut–brain interface

PD, traditionally characterized by motor dysfunction and dopaminergic neuronal loss, has increasingly been associated with alterations in gut microbiota composition, immune activation, and synaptic dysregulation within central neural circuits (Park et al., 2023). Within a systems-level framework, PD can be viewed not only as NDDs but also as a disorder of gut–immune–brain communication, where microbial imbalance and metabolite signaling contribute to synaptic and neuronal dysfunction. Emerging evidence suggests that probiotics may exert beneficial effects not only through anti-inflammatory and antioxidant mechanisms but also by modulating synaptic plasticity, neuronal connectivity, and epigenetic regulation of gene expression. Importantly, probiotic effects are increasingly understood as strain-specific and mechanistically heterogeneous, involving microbial restoration, metabolite production (e.g., SCFAs, GABA), and modulation of host immune–epigenetic signaling pathways. In this context, several probiotic strains—including Bifidobacterium breve, Bifidobacterium animalis, Lactobacillus reuteri, and Clostridium butyricum—have shown beneficial effects in experimental PD models, particularly through converging immune, metabolic, and synaptic pathways (Table 1; Figure 1).

Table 1

Probiotic strainAnimal model/PD inductionDuration of treatmentMechanism exploredEffect on synaptic plasticityGut microbiota modulationSCFA levelsKey outcomesRef
B. breve CCFM1067MPTP-induced mice5 weeksAnti-inflammatory, antioxidant, BBB and gut barrier protectionNot directly assessed↑ Bifidobacterium, Akkermansia; ↓ Escherichia-Shigella↑ Acetate, ButyrateProtected dopaminergic neurons; reduced glial activation and inflammation(Li et al., 2022)
B. animalis subsp. lactis MH-0226-OHDA-induced ratsNot specifiedAnti-inflammatory, mitochondrial function, antioxidant activityNot directly assessedPromoted beneficial taxa↑ SCFA productionImproved motor function, reduced inflammation, protected neurons(Tsao et al., 2024)
L. reuteri (via GABA)MPTP-induced miceNot specifiedFerroptosis inhibition via AKT-GSK3β-GPX4 axisNot directly assessedNot specifiedNot mentionedAlleviated PD symptoms via GABA signaling and ferroptosis inhibition(Dong et al., 2025)
Clostridium butyricumMPTP-induced mice4 weeksGut microbiota–GLP-1 signaling pathwayImproved synaptic dysfunctionRestored microbiota compositionNot directly mentionedAmeliorated motor deficits, neuron loss, and microglia activation(Sun et al., 2021)
B. breve A1 (MCC1274)MPTP-induced mice4 daysNeuropsin modulationRestored postsynaptic protein and spine densityNot specifiedNot mentionedImproved hippocampal plasticity and memory extinction(Ishii et al., 2021)

Synaptic plasticity, probiotic intervention, and Parkinson’s disease: An integrated perspective.

MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; BBB, blood–brain barrier; 6-OHDA, 6-hydroxydopamine; AKT–GSK3β–GPX4 axis, protein kinase B–glycogen synthase kinase-3 beta–glutathione peroxidase 4 signaling pathway; GABA, gamma-aminobutyric acid.

5.1 Gut microbial restoration and SCFA-mediated epigenetic–synaptic coupling

Across multiple experimental models, probiotics consistently restore gut microbial balance by increasing beneficial taxa such as Bifidobacterium and Akkermansia while reducing pro-inflammatory bacteria such as Escherichia–Shigella. This microbial reshaping is consistently associated with increased production of SCFAs, particularly acetate and butyrate, which function as key epigenetic regulators through HDAC inhibition and modulation of inflammatory gene transcription. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine-6 models, this SCFA increase correlates with reduced dopaminergic neurodegeneration, improved mitochondrial function, and suppression of neuroinflammatory signaling (Li et al., 2022; Tsao et al., 2024). Mechanistically, these findings suggest that probiotic-induced neuroprotection is mediated not only by anti-inflammatory effects but also by SCFA-driven epigenetic reprogramming of neuronal and glial cells, leading to a more anti-inflammatory transcriptional state.

5.2 Metabolite-specific neuroprotection and synaptic stabilization

Beyond SCFAs, microbial metabolites such as GABA have been identified as direct neuromodulators. Lactobacillus reuteri–derived GABA has been shown to suppress ferroptosis through activation of the AKT–GSK3β–GPX4 signaling pathway, thereby protecting dopaminergic neurons and preserving synaptic integrity (Dong et al., 2025). This highlights a second mechanistic axis in which probiotics influence synaptic stability through direct neurotransmitter production, linking microbial metabolism to neuronal survival pathways independent of classical immune modulation.

5.3 Gut–brain hormonal signaling and synaptic plasticity

Probiotics such as Clostridium butyricum enhance glucagon-like peptide-1 (GLP-1) signaling both in the gut and brain, promoting neuronal survival, synaptic remodeling, and motor recovery (Sun et al., 2021). GLP-1–mediated effects represent a gut–brain endocrine pathway that converges with SCFA- and immune-mediated signaling, suggesting that probiotic interventions act through multi-layered regulatory networks rather than single pathways. Additionally, normalization of SCFA receptors (GPR41/43) indicates that probiotic effects extend to receptor-level reprogramming of host metabolic sensing systems.

5.4 Hippocampal plasticity and synaptic protein remodeling

In hippocampus-dependent cognitive domains, Bifidobacterium breve A1 restores synaptic proteins such as PSD-95 and synaptophysin and normalizes neuropsin expression, while also improving dendritic spine density in CA1 neurons (Ishii et al., 2021). These effects indicate that probiotics not only modulate neurotransmitter systems but also directly regulate synaptic structural proteins and proteolytic enzymes involved in synaptic remodeling, thereby contributing to cognitive resilience in PD.

5.5 Integrated mechanistic synthesis

Collectively, these findings converge on a unified mechanistic framework in which probiotics modulate PD pathology through three interconnected axes:

  • Microbial restoration and immune rebalancing

  • Metabolite-mediated epigenetic regulation (SCFAs, GABA)

  • Hormonal and neurotransmitter-like signaling (GLP-1, GABA pathways)

These axes converge at the level of neuronal and glial cells, where they regulate chromatin accessibility, inflammatory gene expression, mitochondrial function, and synaptic protein stability. Thus, probiotic interventions should not be interpreted as isolated strain-specific effects but rather as systems-level modulators of the gut–microbiota–immune–epigenetic–synaptic axis in PD. This integrated perspective aligns with the proposed framework of infection-driven dysbiosis leading to epigenetic remodeling, microglial activation, and synaptic dysfunction.

6 Synaptic plasticity and probiotic intervention in AD: insights from experimental and clinical studies

AD is characterized by progressive cognitive decline driven by synaptic loss, chronic neuroinflammation, and neuronal network dysfunction. Beyond classical amyloid and tau pathology, increasing evidence highlights AD as a systems-level disorder involving dysregulation of the gut–brain axis, in which intestinal microbiota influence brain function through immune, metabolic, and epigenetic pathways (Pasupalak et al., 2024). Importantly, this axis can be conceptualized as a continuous signaling cascade linking gut microbial imbalance to central synaptic dysfunction. Within this framework, probiotics and prebiotics are increasingly considered modulators of brain plasticity through their ability to reshape gut microbial composition and downstream host signaling rather than acting as isolated therapeutic agents (Table 2; Figure 2).

Table 2

Study typeModel/SubjectsInterventionDurationMechanism of actionEpigenetic/Molecular targetsNeuroprotective/Inflammatory outcomesCognitive/Behavioral outcomeKey findings/NotesRef
Animal Studyβ-amyloid injected ratsProbiotic mixtureNot specifiedAntioxidant enhancement, synaptic plasticity restorationTAC, MDA, LTPReduced oxidative stress and improved synaptic transmissionImproved spatial memoryProbiotic restored LTP and improved maze navigation(Asl et al., 2019)
Clinical TrialAD patientsMulti-strain probiotic12 weeksIncreased BDNF, reduced IL-1β, increased SODBDNF, IL-1β, SODReduced inflammation and oxidative stressNon-significant trend toward cognitive improvementProbiotic increased BDNF and reduced inflammatory markers(Hsu et al., 2023)
Animal StudyAPP/PS1 miceSaccharomyces boulardiiNot specifiedTLR pathway inhibition, microglia regulationTLR, CD11b, IL-6, IL-1βReduced neuroinflammation, improved synaptic integrityImproved cognitive performanceProbiotic improved microbiota and neuroinflammation(Ye et al., 2022)
Animal Study3×Tg-AD miceLactobacillus plantarum PS12833 daysRegulated PPA, GSK3β, gliosisGSK3β, pT231 tauReduced gliosis and AD pathologyPrevented cognitive dysfunctionPS128 modulates propionic acid and kinase activity(Huang et al., 2021)
Animal StudyAppNL-G-F miceVSL#3 probiotic8 weeksIncreased SCFAs, especially acetate and lactateSCFAs, c-FosMinimal histological change; increased c-FosPotential activation of neuronal pathwaysAltered microbiota and SCFA levels(Kaur et al., 2020)
Animal StudyAPP/PS1 miceEncapsulated L. plantarumNot specifiedRestored SCFA levels, gut barrier integrityPSD-95, Aβ, tauReduced neuroinflammation and Aβ/tau pathologyImproved cognitive functionsLbL encapsulation improved probiotic efficacy(Hu et al., 2024)
Animal StudyWild-type miceB. breve MCC12744 monthsAkt/GSK-3β pathway modulationGSK3β, tau, AβReduced Aβ and phosphorylated tauImproved memory and synaptic proteinsAttenuated AD pathology in WT mice(Ahmed Abdellatif Abdelhamid, 2023)
Animal Study17-month-old AppNL-G-F miceB. breve MCC1274Not specifiedReduced JNK/ERK stress, tau phosphorylationJNK, ERK, tauReduced inflammation and enhanced synaptic densityAmeliorated memory impairmentImproved neuronal activity and reduced stress(Abdelhamid et al., 2024)
Animal StudyAβ1–42 treated miceB. breve CCFM1025 and WXNot specifiedIncreased BDNF, FNDC5, PSD-95BDNF, PSD-95Improved synaptic plasticityImproved cognitionGut microbiota modulation improved outcomes(Zhu et al., 2021)
Animal StudyAPP/PS1 miceFOS6 weeksGLP-1/GLP-1R modulation, microbiota restorationJNK, PSD-95, synapsin IReduced neurodegeneration and inflammationAmeliorated cognitive deficitsPrebiotics altered gut-brain signaling(Sun et al., 2019)
Clinical TrialSevere AD patientsProbiotic mixture12 weeksNo pronounced effect in severe ADNO, GSH, TAC, IL-6Minimal impact on biomarkersNo cognitive improvementAD severity affects response to probiotics(Agahi et al., 2018)

Synaptic plasticity and probiotic intervention in Alzheimer’s disease: Insights from experimental and clinical studies.

AD, Alzheimer’s disease; BDNF, brain-derived neurotrophic factor; IL-1β, interleukin-1 beta; SOD, superoxide dismutase; APP/PS1 mice, amyloid precursor protein/presenilin-1 double-transgenic mice; TLR, Toll-like receptor; CD11b, cluster of differentiation 11b (integrin αM); IL-6, interleukin-6; GSK3β, glycogen synthase kinase-3 beta; SCFAs, short-chain fatty acids; c-Fos, cellular Fos proto-oncogene (a marker of neuronal activity); AppNL-G-F mice, knock-in Alzheimer’s disease mouse model carrying the Swedish (NL), Arctic (G), and Iberian (F) mutations in the amyloid precursor protein gene; Aβ, amyloid-beta peptide; JNK, c-Jun N-terminal kinase; ERK, extracellular signal-regulated kinase.

Figure 2

6.1 Restoration of synaptic plasticity through probiotics in animal models

Across experimental models, probiotic and prebiotic interventions consistently improve synaptic function and cognitive performance, and these effects are tightly associated with restoration of gut microbial composition and increased production of neuroactive metabolites such as SCFAs. These metabolites, particularly butyrate and acetate, are strongly implicated in epigenetic regulation through HDAC inhibition, which facilitates transcriptional activation of genes involved in synaptic maintenance and neuroprotection. Across different AD models, improvements in hippocampal synaptic plasticity, including restoration of long-term potentiation and enhancement of synaptic protein expression such as PSD-95 and synaptophysin, are commonly observed following probiotic administration (Asl et al., 2019; Hu et al., 2024). These synaptic changes occur in parallel with reductions in neuroinflammatory signaling, particularly through suppression of microglial activation and Toll-like receptor–mediated pathways, suggesting that immune modulation is a central component of probiotic action (Ye et al., 2022). In addition, several studies indicate that probiotic-induced modulation of intracellular signaling pathways such as GSK3β contributes to reduced tau phosphorylation and improved neuronal stability (Huang et al., 2021). Importantly, increases in neuronal activity markers such as c-Fos further suggest that microbial metabolites can enhance functional synaptic activation even when amyloid pathology remains relatively unchanged (Kaur et al., 2020). Taken together, these findings support a mechanistic sequence in which gut microbial modulation alters SCFA availability, which in turn reshapes epigenetic regulation of inflammatory and synaptic genes, ultimately leading to reduced microglial activation and improved synaptic function.

6.2 Influence of specific probiotic strains on synaptic and molecular pathways

Different probiotic strains exert overlapping yet partially distinct effects on synaptic plasticity in AD models, reflecting strain-specific modulation of gut–brain signaling pathways. Bifidobacterium breve strains, for example, improve synaptic integrity by regulating intracellular signaling cascades such as Akt/GSK3β, which are closely involved in tau phosphorylation and neuronal survival (Ahmed Abdellatif Abdelhamid, 2023; Abdelhamid et al., 2024). These molecular changes are accompanied by increased expression of synaptic proteins and reduced microglial activation, indicating simultaneous regulation of neuronal and immune components of AD pathology. Other strains such as Lactobacillus plantarum PS128 modulate synaptic stability through regulation of glycogen synthase kinase 3β activity, reduction of tau phosphorylation, and restoration of postsynaptic density protein 95, effects that are associated with reduced gliosis and improved metabolic balance via propionic acid–related pathways (Huang et al., 2021). Similarly, Bifidobacterium breve MCC1274 improves synaptic integrity and neuronal activity by suppressing stress-related signaling pathways, reducing tau hyperphosphorylation, and enhancing synaptic protein expression, thereby supporting synaptic plasticity through amyloid-independent mechanisms (Abdelhamid et al., 2024). Despite these mechanistic differences, a consistent pattern emerges in which all probiotic strains ultimately converge on the regulation of synaptic plasticity through coordinated effects on microbial metabolites, inflammatory signaling, and intracellular neuronal pathways. Importantly, these converging pathways intersect at the level of epigenetic regulation and microglial phenotype modulation, providing a unified explanation for their shared synaptic benefits.

6.3 Clinical studies: translational impact on human cognitive function

Clinical evidence further supports the mechanistic relevance of gut microbiota modulation in AD, although cognitive outcomes remain more variable compared to experimental models. In patients receiving multi-strain probiotic formulation containing Bifidobacterium longum subsp. infantis BLI-02, Bifidobacterium breve Bv-889, Bifidobacterium animalis subsp. lactis CP-9, Bifidobacterium bifidum VDD088, and Lactobacillus plantarum PL-02, increases in BDNF and antioxidant capacity, along with reductions in pro-inflammatory cytokines such as IL-1β, suggest a shift toward a more neuroprotective systemic environment (Hsu et al., 2023). These peripheral molecular changes are mechanistically consistent with central effects observed in experimental models, suggesting that systemic immune and metabolic modulation may indirectly influence brain synaptic plasticity via gut–brain signaling pathways. However, the limited cognitive improvement observed in some trials, particularly in advanced stages of AD, suggests that therapeutic efficacy is strongly dependent on disease progression and residual synaptic plasticity (Agahi et al., 2018).

7 Microbiota–epigenome interactions in neurodegeneration: insights from AD and PD

gut–brain axis represents an integrated systems-level regulatory network in which infection-driven dysbiosis, microbial metabolites, and inflammatory signaling converge to regulate miRNA expression, transcriptional programs, microglial activation, and synaptic function. Within this framework, gut microbiota act as upstream modulators of neuroimmune and epigenetic-like mechanisms that shape neurodegenerative vulnerability in AD and PD (Table 3).

Table 3

Study type/ModelTreatment/FactorInflammatory pathwayInflammatory markersEpigenetic componentKey findingsRef
Bioinformatics analysis of AD patient samplesGut dysbiosis (NGS + transcriptomics)MAPK, ErbB, Axon GuidanceNot specifiedmiRNAs: let-7c, miR-125b-2, miR-145Dysbiosis correlates with altered miRNAs and AD pathways(Asadifard et al., 2024)
Clinical (8 AD, 8 controls)Natural gut microbiotaJNK, SNARE complexMMSE scoresmiRNAs: miR-3120-3p, miR-6529-5p, miR-124-3p, miR-323a-5pGut microbes and miRNAs linked to cognitive impairment(Lin et al., 2025)
Rotenone-induced PD mouse modelLactobacillus plantarum PS128SOCS1–miR-155–NF-κB axisIL-1β, TNF-α (inferred)miR-155-5p, SOCS1PS128 reduces inflammation via miR-155/SOCS1 modulation(Lee et al., 2023)
Clinical + Rat PD modelLactobacillus rhamnosus NCDC17miR-146a–GDNF signalingNeuroinflammation (GDNF levels)miR-146a → GDNFL. rhamnosus alters miR-146a and GDNF, affecting PD outcome(Wei et al., 2021)

Microbiota–epigenome interactions in AD and PD.

MAPK, mitogen-activated protein kinase; JNK, c-Jun N-terminal kinase; SNARE, soluble N-ethylmaleimide-sensitive factor attachment protein receptor; MMSE, Mini-Mental State Examination; IL-1β, interleukin-1 beta; TNF-α, tumor necrosis factor alpha; SOCS1–miR-155–NF-κB axis, suppressor of cytokine signaling 1–microRNA-155–nuclear factor kappa B signaling axis; GDNF, glial cell line-derived neurotrophic factor.

7.1 Microbiota–miRNA regulatory axis in neurodegeneration

Gut dysbiosis is strongly associated with altered miRNA expression that regulates synaptic signaling and neuroinflammation. Asadifard et al. (2024) reported reduced abundance of SCFA-producing bacteria (Firmicutes, Clostridia, Faecalibacterium) together with disruption of 619 shared gut–brain genes. These molecular changes converge on axon guidance, MAPK, and ErbB signaling pathways, which are essential for synaptic plasticity and neuronal stress responses. Key miRNAs such as let-7c, miR-125b-2, and miR-145 were identified as central regulatory nodes controlling these pathways (Asadifard et al., 2024). Lin et al. (2025) further demonstrated that circulating exosomal miRNAs (miR-124-3p, miR-6529-5p, miR-3120-3p, miR-323a-5p) correlate with microbial composition and cognitive decline. Importantly, these miRNAs regulate neurotrophin signaling, synaptic transmission, and cellular transport, indicating that gut microbes influence brain function through systemic miRNA-mediated regulatory circuits rather than isolated molecular changes.

7.2 Microbial regulation of miRNAs and neuroinflammation in PD

In PD, microbiota–miRNA interactions regulate neuroinflammatory signaling and dopaminergic neuronal survival. Zhang Lee et al. (2023) demonstrated that Lactobacillus plantarum PS128 reduces miR-155-5p expression, restoring SOCS1 levels and suppressing NF-κB/STAT1-mediated inflammation. This establishes a direct microbial–miRNA–transcription factor axis linking gut microbiota to CNS immune regulation. Wei et al. (2021) reported that miR-146a negatively regulates glial cell line-derived neurotrophic factor (GDNF), thereby reducing dopaminergic neuron survival. Elevated miR-146a levels were associated with gut dysbiosis, suggesting microbial control of neurotrophic signaling via post-transcriptional regulation. Zhao et al. (2021) further demonstrated that microbial toxins such as LPS activate TLR4–NF-κB signaling, sustaining inflammatory gene expression and promoting epigenetic-like transcriptional reprogramming.

7.3 Microbiota-driven transcriptomic reprogramming and synaptic plasticity

Microbial interventions induce widespread transcriptomic remodeling in brain and gut tissues, affecting synaptic plasticity, inflammation, and neuronal survival. Webberley et al. (2022) showed that a multi-strain probiotic mixture known as Lab4b, consisting of Lactobacillus salivarius CUL61, Lactobacillus paracasei CUL08, Bifidobacterium bifidum CUL20, and Bifidobacterium animalis subsp. lactis CUL34 upregulated synaptic genes including CPLX2, GRIA1, and NSMF, with a trend toward increased BDNF expression. These findings indicate that probiotics enhance synaptic plasticity primarily through transcriptional activation of neuronal connectivity pathways rather than amyloid clearance alone (Table 4). Webberley et al. (2023) further demonstrated that Lab4P reduced inflammatory gene expression while preserving hippocampal spine density under metabolic stress conditions. Hu and Shao (2022) showed that Lactobacillus pentosus upregulates BIRC3, which suppresses NLRC4 inflammasome activation and reduces IL-1β/IL-18-mediated pyroptosis. This highlights probiotic control of inflammasome-driven transcriptional programs involved in neuroinflammation. Chen et al. (2017) demonstrated that fructooligosaccharides reshape gut microbiota composition and regulate genes involved in neurotransmitter synthesis, mitochondrial function, and inflammatory signaling. These transcriptomic alterations were associated with reduced Aβ deposition and tau pathology, linking microbial metabolism to host gene regulation across the gut–brain axis. He et al. (2024) reported that Danggui Shaoyao San significantly suppresses IL-1β, TNF-α, and IL-6 via NF-κB inhibition while modulating gut microbial composition, particularly enriching Ligilactobacillus species (Table 5). Wang et al. (2022) demonstrated that Lactobacillus plantarum MA2 inhibits the TLR4/MYD88/NLRP3 signaling axis, resulting in reduced microglial activation, improved intestinal barrier integrity, and decreased amyloid pathology.

Table 4

Study type/modelTreatment/interventionTargeted pathway(s)Inflammatory markersEpigenetic involvementKey resultsRef
Animal model (3xTg-AD mice) + HFDLab4b probiotic consortiumNeurogenesis, anti-inflammatory pathwaysSystemic and local inflammatory responsesNot directly studied (but gene expression modulated)Improved cognition and spine density; reduced inflammation; altered gut microbiota(Webberley et al., 2022)
Animal model (3xTg-AD mice); in vitro (SH-SY5Y)Lab4P probiotic consortiumAmyloid protection, inflammation, neuroplasticityAnti-inflammatory gene expression (brain, in vitro)Not specified, but gene expression changes in hippocampusImproved cognition; protective against β-Amyloid toxicity; enhanced mRNA of synaptic genes(Webberley et al., 2023)
In vitro cell model (SH-SY5Y neurons)Lactobacillus pentosus S-PT84BIRC3/NLRC4 pyroptosis signalingIL-1β, IL-18, cleaved caspase-1, GSDMD-NBIRC3 gene regulation (post-transcriptional, epigenetic relevance)Reduced pyroptosis; restored BIRC3; suppressed inflammation via NLRC4 inhibition(Hu and Shao, 2022)
Animal model (D-galactose + Aβ1–42 in rats)Fructooligosaccharides from Morinda officinalis (OMO)Microbiota-gut-brain axis; neurotransmitter synthesis; intestinal transcriptomeCytokines in brain; inflammation-related genes in intestineTranscriptomic shifts in gut and brain; altered gene expressionImproved memory and brain histology; reduced oxidative stress and inflammation; shifted microbiota; gene expression changes in gut and brain(Chen et al., 2017)

Transcriptomic shifts and neuroinflammation via probiotics.

HFD, high-fat diet; IL-1β, interleukin-1 beta; IL-18, interleukin-18; GSDMD-N, N-terminal fragment of gasdermin D; 3xTg-AD mice, triple-transgenic Alzheimer’s disease mouse model (APP, PSEN1, and tau mutations).

Table 5

Study type and modelTreatment/interventionTargeted pathway(s)Inflammatory markers involvedEpigenetic involvementKey resultsRef
Commentary, AD patients and molecular evidenceGut-derived neurotoxins (e.g., LPS, bacterial amyloids, sncRNA)Innate immunity, neurovascular signalingNot explicitly named; general neuroinflammationsncRNAsNeurotoxins like LPS and sncRNAs cross barriers, enter CNS, and contribute to AD-related inflammation and degeneration.(Zhao et al., 2021)
Experimental, d-galactose/AlCl3-induced AD ratsProbiotic (Lactobacillus plantarum MA2)TLR4/MYD88/NLRP3 signalingNot detailed in abstractNot mentionedMA2 improved cognition, reduced Aβ and inflammation, and reshaped microbiota.(Wang et al., 2022)
Experimental, STZ-induced AD ratsHerbal compound (Danggui Shaoyao San)Gut–brain metabolite modulation, Purine and Nicotinate metabolismIL-1β, IL-6, TNF-αNot mentionedDSS enhanced memory, reduced inflammation and oxidative stress, and shifted microbiota and metabolites.(He et al., 2024)

Gut microbiota and epigenetic regulation of inflammatory pathways.

sncRNA, small non-coding RNA; IL-1β, interleukin-1 beta; IL-6, interleukin-6; TNF-α, tumor necrosis factor alpha; STZ-induced AD rats, streptozotocin-induced Alzheimer’s disease rat model; TLR4/MYD88/NLRP3 signaling, Toll-like receptor 4/myeloid differentiation primary response protein 88/NOD-like receptor family pyrin domain containing 3 signaling pathway.

7.4 Integrated inflammatory signaling and epigenetic-like regulation

Inflammatory signaling pathways act as central hubs connecting microbial dysbiosis to transcriptional and epigenetic regulation. PS128-mediated downregulation of miR-155-5p restores SOCS1 expression and suppresses NF-κB signaling (Lee et al., 2023), while BIRC3 activation inhibits NLRC4 inflammasome-mediated pyroptosis (Hu and Shao, 2022). This cascade can be summarized as:

  • gut dysbiosis → microbial metabolites/toxins → miRNA dysregulation → transcription factor activation (SOCS1, BIRC3, NF-κB, TLR4) → microglial activation → synaptic dysfunction

Zhao et al. (2021) demonstrated that persistent LPS exposure sustains NF-κB-driven inflammatory gene expression and induces epigenetic-like chromatin remodeling. Although not a classical epigenetic enzyme, NF-κB signaling can influence histone acetylation and chromatin accessibility.

Importantly, previous mechanistic frameworks also emphasize that chronic neuroinflammation is tightly linked with persistent activation of innate immune signaling cascades and downstream transcriptional reprogramming events, which collectively bridge microbial signals to long-term changes in brain immune tone (Zhao et al., 2021; Wang et al., 2025). Within this context, inflammatory mediators such as cytokines and pattern recognition receptor pathways act as functional intermediates between microbial stimuli and epigenetic-like chromatin regulation, reinforcing the concept that gut-derived signals can induce durable transcriptional memory in microglia and other CNS-resident cells (Zhao et al., 2021; Wang et al., 2025). He et al. (2024) and Wang et al. (2022) further confirm that suppression of NF-κB/TLR4/NLRP3 axes reduces neuroinflammation and restores microbial–metabolic balance.

7.5 Therapeutic implications

Microbiota-targeted therapies, including probiotics, prebiotics, and dietary interventions, represent promising strategies for NDDs. These interventions exert multi-level effects across miRNA regulation, transcriptional reprogramming, metabolic signaling, and neuroinflammatory suppression. Wei et al. (2021) highlight that excessive miR-146a signaling may worsen neurodegeneration by suppressing GDNF, emphasizing the importance of strain-specific probiotic selection. Zhang Lee et al. (2023) further demonstrate that PS128 restores dopaminergic signaling through miRNA modulation. Webberley et al. (2023) and Hu and Shao (2022) show that probiotic-derived metabolites directly influence neuronal gene expression and synaptic stability. Overall, this section supports a unified mechanistic framework in which gut microbiota regulate neurodegeneration through coordinated modulation of metabolites, miRNAs, transcriptional networks, inflammatory signaling, and synaptic integrity across AD and PD.

8 Infection-driven gut dysbiosis and barrier dysfunction as upstream determinants of systemic endotoxemia

Mounting clinical and experimental evidence suggests that systemic infections are consistently accompanied by measurable alterations in gut microbial ecology and intestinal barrier integrity. These changes extend beyond local gastrointestinal disturbances and are increasingly recognized as part of a reproducible host–microbiome response to infection. A synthesis of key clinical studies examining infection-associated dysbiosis, barrier dysfunction, and endotoxemia is summarized in Table 6.

Table 6

Infection contextSample typeDysbiosis signature (Composition)Barrier dysfunction markerMicrobial translocation markerFunctional/clinical outcomeRef
COVID-19 (sepsis)SerumMicrobiota-linked metabolic shift (↑TMAO)—↑LPSSeptic shock severity(Polat et al., 2024)
COVID-19 pneumoniaSerum—↑ZO-1↑EndotoxinSystemic inflammation(Assimakopoulos et al., 2021)
COVID-19Plasma↑F/B ratio, ↓Bacteroides↑FABP2↑LPS, PGNGut barrier disruption(Prasad et al., 2022)
COVID-19Stool↓Faecalibacterium, ↓Bifidobacteria——Disease severity linkage(Yeoh et al., 2021)
SepsisPlasma—↑Zonulin—Increased intestinal permeability(Klaus et al., 2013)
COVID-19PlasmaEnterobacteriaceae enrichment↑Zonulin—Cytokine elevation(Souza et al., 2025)
AVL/HIV coinfectionPlasma—↑IFABP↑LPS, sCD14Immune activation(Santos-Oliveira et al., 2013)
HIV therapy (MPI)Plasma——↑LBP, sCD14Monocyte activation(Torres et al., 2014)
HIV therapy (mtDRV)Plasma——↓LPS (suppressed VL)Reduced T-cell activation(BenMarzouk-Hidalgo et al., 2015)
HIV (perinatal)Plasma——↑LPS, ↑LBP, ↑sCD14Early immune activation(Papasavvas et al., 2011)
HIV transmission (infants)Plasma—↑Permeability↑LPSInfection acquisition risk(Kourtis et al., 2013)
DengueBlood↑Proteobacteria, ↑EscherichiaLeaky gut↑LPS, ↑β-D-glucanSevere disease progression(Chancharoenthana et al., 2022)

Infection-associated dysbiosis, barrier dysfunction, and microbial translocation signatures.

COVID-19, coronavirus disease 2019; TMAO, trimethylamine N-oxide; LPS, lipopolysaccharide; ZO-1, zonula occludens-1; FABP2, fatty acid–binding protein 2 (intestinal fatty acid–binding protein); PGN, peptidoglycan; F/B ratio, Firmicutes-to-Bacteroidetes ratio; VL/HIV, visceral leishmaniasis/human immunodeficiency virus coinfection; LBP, lipopolysaccharide-binding protein; sCD14, soluble cluster of differentiation 14; β-D-glucan, beta-D-glucan.

8.1 Infection-associated dysbiosis: a reproducible compositional signature

Accumulating clinical and translational evidence suggests that infectious diseases can trigger a relatively conserved shift in gut microbial composition that may act as a biological signature of systemic immune imbalance. In patients with coronavirus disease 2019 (COVID-19), Yeoh et al. (2021) reported substantial alterations in intestinal microbiota compared with non-infected controls, regardless of therapeutic exposure. Specifically, microbial taxa known for their anti-inflammatory and immunoregulatory roles—such as Faecalibacterium prausnitzii, Eubacterium rectale, and members of the Bifidobacterium genus—were consistently reduced during active infection. Notably, these compositional disturbances did not immediately revert following viral clearance. Instead, depletion of these beneficial commensals persisted for several weeks after recovery, suggesting that infection-associated dysbiosis may outlast the acute phase of the disease. Furthermore, these microbiota shifts were linked with elevated systemic inflammatory markers, including C-reactive protein and liver-associated enzymes, indicating a close relationship between microbial imbalance and host immune responses (Yeoh et al., 2021). Parallel findings were documented by Prasad et al. (2022), who explored circulating microbial profiles in plasma samples obtained from hospitalized individuals with SARS-CoV-2 infection. Their analysis revealed systemic microbial imbalance characterized by a decline in Bacteroides populations alongside an increased Firmicutes-to-Bacteroidetes (F/B) ratio—a compositional feature frequently associated with inflammatory states and impaired epithelial integrity. In addition to taxonomic changes, infected patients exhibited significantly elevated levels of intestinal permeability markers such as fatty acid binding protein-2. Simultaneously, microbial-derived antigens, including LPS and peptidoglycan fragments, were detected at higher concentrations in the circulation. These findings strongly support the occurrence of microbial translocation from the intestinal lumen into the bloodstream during infection. The convergence of increased F/B ratio with heightened permeability markers suggests that compositional dysbiosis is functionally linked with epithelial barrier compromise, thereby facilitating systemic exposure to pro-inflammatory microbial products (Prasad et al., 2022). Further mechanistic insight into this reproducible microbial signature has been provided by Souza et al. (2025), who evaluated bacteriome dynamics in patients experiencing both acute and post-acute SARS-CoV-2 infection. Their study demonstrated marked alterations in microbial diversity that were accompanied by increased plasma concentrations of pro-inflammatory cytokines. Importantly, expansion of opportunistic bacterial groups, including Enterobacteriaceae and Escherichia–Shigella, showed a positive association with circulating zonulin levels. Zonulin is recognized as a key regulator of tight junction integrity and plays a central role in modulating epithelial permeability. The observed correlation suggests that infection-associated microbial changes may directly influence barrier stability by activating zonulin-mediated signaling pathways.

Consequently, dysbiosis-driven increases in zonulin may promote paracellular leakage, enabling the systemic dissemination of microbial metabolites and structural components that can further amplify immune activation through pattern recognition receptors such as TLR4 (Souza et al., 2025). Comparable infection-related dysbiotic patterns have also been observed in viral diseases beyond COVID-19. In patients with dengue infection, Chancharoenthana et al. (2022) identified evidence of gut-derived microbial translocation into the systemic circulation, particularly in individuals with severe clinical manifestations. Blood bacteriome profiling revealed an increased abundance of Proteobacteria and Escherichia species, accompanied by reduced representation of protective commensals such as Bifidobacterium. These taxonomic shifts occurred alongside elevated lactulose-to-mannitol ratios, indicating compromised intestinal barrier integrity, as well as increased circulating concentrations of LPS and β-D-glucan. Moreover, the presence of microbial components in plasma correlated with activation of innate immune cell populations, including natural killer cells and pro-inflammatory monocyte subsets (Chancharoenthana et al., 2022).

8.2 Barrier dysfunction and endotoxemia: functional signatures of infection-associated dysbiosis

While infection-associated dysbiosis is initially reflected by compositional shifts in the gut microbial community, its downstream impact becomes more evident through functional alterations that compromise intestinal barrier integrity. A disrupted epithelial interface allows microbial-derived molecules to escape the gut lumen and enter the systemic circulation, where they can modulate host immune responses. In this regard, clinical observations from COVID-19–associated pneumonia have provided early insight into the physiological consequences of gut barrier impairment. Assimakopoulos et al. (2021) reported significantly elevated circulating levels of both endotoxin and zonula occludens-1 (ZO-1) in hospitalized patients compared with healthy individuals. As ZO-1 is a key structural component of epithelial tight junctions, its presence in peripheral blood likely reflects damage to the intestinal epithelial layer and loosening of paracellular connections (Assimakopoulos et al., 2021). A similar disruption of mucosal integrity has also been documented in patients with sepsis. Klaus et al. (2013) demonstrated that circulating levels of zonulin—a physiological regulator of tight junction permeability—were significantly elevated in septic individuals relative to both postoperative controls and healthy subjects. Increased zonulin activity is associated with junctional disassembly and enhanced intestinal permeability, which may allow luminal microbial components to reach the bloodstream (Klaus et al., 2013). Further support for this mechanism comes from studies investigating co-infected populations. In patients with visceral leishmaniasis and human immunodeficiency virus (HIV), Santos-Oliveira et al. (2013) identified markedly increased plasma concentrations of LPS alongside elevated levels of I-FABP, a biomarker of enterocyte injury. Elevated I-FABP indicates epithelial cell damage within the gut mucosa, which may facilitate the movement of microbial endotoxins across the compromised barrier. Notably, circulating LPS levels in these patients were positively correlated with immune activation markers and inflammatory cytokines such as IL-6 and IL-8 (Santos-Oliveira et al., 2013).

Evidence derived from pediatric HIV cohorts provides additional clinical relevance to these observations. Papasavvas et al. (2011) reported increased plasma concentrations of LPS as well as host endotoxin-binding molecules, including soluble CD14 (sCD14) and LPS-binding protein (LBP), in perinatally infected infants during early life. Infants who experienced delayed initiation of antiretroviral therapy exhibited consistently higher levels of these microbial translocation markers than those treated earlier (Papasavvas et al., 2011). Comparable findings were reported in the Breastfeeding, Antiretrovirals, and Nutrition study by Kourtis et al. (2013), in which plasma LPS levels in infants were associated with an increased risk of HIV acquisition through breast-feeding. Elevated endotoxin concentrations prior to infection were also linked to reduced growth parameters (Kourtis et al., 2013). The influence of therapeutic regimens on microbial translocation markers has also been explored in adult HIV populations. Torres et al. (2014) compared patients receiving protease inhibitor monotherapy with those undergoing combination antiretroviral therapy and observed higher levels of microbial translocation markers, including LBP, in the monotherapy group. These alterations were accompanied by increased concentrations of soluble monocyte activation markers such as sCD14 and elevated IL-6 levels (Torres et al., 2014). Conversely, BenMarzouk-Hidalgo et al. (2015) examined HIV-infected individuals undergoing ritonavir-boosted darunavir monotherapy over a 24-month follow-up period and found that reductions in circulating LPS concentrations were mainly observed in patients maintaining continuous viral suppression (BenMarzouk-Hidalgo et al., 2015). Additional clinical data linking endotoxemia to disease severity have been reported in patients with COVID-19–related septic shock. Polat et al. (2024) demonstrated that circulating LPS levels were significantly higher in septic patients compared with non-septic infected individuals and healthy controls. Elevated endotoxin concentrations were accompanied by increased levels of trimethylamine N-oxide (TMAO), a microbiota-derived metabolite associated with inflammatory states. The concurrent rise in LPS and TMAO in severely ill patients suggests that gut-derived microbial products may contribute to systemic inflammatory burden and clinical deterioration during infection (Polat et al., 2024).

9 Microbiota-derived metabolites as epigenetic regulators of host immune programming

Beyond compositional shifts in microbial communities and barrier dysfunction, accumulating evidence suggests that microbiota-derived metabolites actively participate in reshaping host immune responses at the epigenetic level. In particular, SCFAs such as butyrate have been shown to modulate HDAC activity, thereby altering chromatin accessibility and inflammatory gene transcription (Chang et al., 2014; Parada‐Venegas et al., 2025). Similarly, bacterial LPS can initiate TLR4-dependent signaling cascades that induce histone methylation and acetylation changes at the promoters of pro-inflammatory genes, enabling sustained transcriptional responsiveness (Yoshida et al., 2015). In parallel, microbiota-derived tryptophan metabolites have emerged as endogenous ligands for the aryl hydrocarbon receptor (AhR), influencing epithelial integrity and immune homeostasis through transcription factor-mediated gene regulation (Scott et al., 2020; Tan et al., 2022).

9.1 Butyrate-mediated HDAC inhibition and LPS-driven chromatin reprogramming in host immune cells

A growing body of mechanistic evidence indicates that microbiota-derived SCFAs, particularly butyrate, function not only as metabolic substrates but also as epigenetic regulators capable of modifying host inflammatory responses through histone-modifying enzymes. One of the earliest demonstrations of this concept was provided by Chang et al. (2014), who showed that butyrate suppresses LPS-induced inflammatory mediator production in intestinal macrophages through inhibition of HDAC activity, thereby promoting immune tolerance toward commensal microbiota without broadly impairing immune competence (Chang et al., 2014). Consistently, Jiang et al. (2020) reported that sodium butyrate attenuates LPS-induced inflammatory gene expression in macrophages by suppressing NF-κB activation and NLRP3 inflammasome signaling, while simultaneously preventing histone deacetylation at inflammatory gene loci (Jiang et al., 2020). Parallel observations in epithelial systems have further indicated that SCFAs such as sodium butyrate and sodium propionate can selectively inhibit class I HDAC isoforms and enhance histone H3 acetylation at regulatory regions involved in inflammatory signaling pathways (Silva et al., 2018). Beyond immune cells, transcriptional analyses have revealed that butyrate induces widespread gene expression changes in metabolically active tissues, including endothelial and skeletal muscle cells, consistent with its activity as a potent HDAC inhibitor (Chriett et al., 2019). These chromatin-level changes appear to extend to pathological contexts. For instance, Zhao et al. (2025) demonstrated that butyrate-mediated suppression of HDAC2 expression attenuates IL-6/STAT3 signaling in hepatic stellate cells, thereby reducing fibrotic activation in biliary atresia models. Similarly, recent transcriptomic data suggest that butyrate treatment can modify histone lactylation patterns associated with inflammatory gene expression in pulmonary immune cells, leading to reduced MAPK- and Janus kinase–signal transducer and activator of transcription-mediated inflammatory signaling in experimental models of chronic obstructive pulmonary disease (Jiang et al., 2025). Comparable epigenetic modulation has also been reported in inflamed intestinal tissues, where butyrate targets HDAC3 activity in monocytes and macrophages, resulting in increased H3K9 acetylation and reduced secretion of TNF-α and IL-6 in ex vivo inflammatory bowel disease biopsies (Parada‐Venegas et al., 2025). At the endocrine level, HDAC inhibition by butyrate has been shown to restore histone H3 and H4 acetylation in pancreatic islets exposed to chronic IL-1β stimulation, thereby preserving insulin secretory function and attenuating inflammation-associated transcriptional dysregulation (Pedersen et al., 2024). In parallel, pathogen-associated molecular patterns such as LPS have been shown to induce persistent epigenetic changes through chromatin remodeling pathways. Experimental studies have demonstrated that LPS stimulation enhances histone methylation marks, particularly H3K4me2, at promoters of pro-inflammatory cytokine genes including IL-6 and TNF-α, facilitating their transcriptional activation (Zhao et al., 2019). Additionally, LPS exposure has been reported to dynamically regulate HDAC expression in macrophages, thereby modulating the transcriptional amplitude of inflammatory mediators such as COX-2 and Ccl2 at the promoter level (Aung et al., 2006). Indeed, Yoshida et al. (2015) identified a role for the transcription factor ATF7 in mediating LPS-induced epigenetic memory in macrophages through regulation of repressive histone H3K9me2 marks, leading to sustained basal expression of innate immune genes following initial pathogen exposure.

9.2 Tryptophan-derived microbial metabolites as AhR-mediated epigenetic modulators

In addition to SCFAs, gut microbiota generates a wide range of small-molecule metabolites from dietary amino acids that may participate in host transcriptional regulation. Among these, tryptophan-derived microbial catabolites have increasingly been suggested to act as endogenous modulators of the AhR, a ligand-activated transcription factor involved in immune homeostasis and epithelial barrier maintenance. Emerging experimental evidence indicates that microbiota-derived indole compounds can activate AhR-dependent signaling cascades, thereby influencing downstream gene expression programs related to oxidative stress responses, inflammation, and mucosal integrity (Tan et al., 2022). Several mechanistic studies have demonstrated that microbial tryptophan metabolites, including indole-3-aldehyde, indole-3-ethanol, and indole-3-pyruvate, may exert protective effects on epithelial barrier function through AhR activation in experimental models of intestinal inflammation (Scott et al., 2020). Activation of AhR by these metabolites has been associated with stabilization of apical junctional complexes and actin-associated cytoskeletal regulators, suggesting a potential role in maintaining intestinal permeability under inflammatory conditions. Although the precise molecular targets of these metabolites remain incompletely characterized, available data indicate that AhR-dependent transcriptional responses may contribute to improved barrier resilience by regulating genes involved in epithelial integrity and immune tolerance.

Importantly, not all microbiota-derived metabolites interact with AhR in an equivalent manner. Detailed in vitro characterization of gut microbial tryptophan catabolites has shown that these molecules exhibit varying agonistic or antagonistic activities toward AhR, resulting in ligand-specific transcriptional outcomes (Vyhlídalová et al., 2020). Reporter gene assays and ligand-binding analyses have demonstrated that several indole derivatives can induce nuclear translocation of AhR and promote heterodimer formation with the AhR nuclear translocator, ultimately enhancing binding to target gene promoters such as CYP1A1. Interestingly, recent experimental work indicates that butyrate may further modulate AhR-dependent transcriptional responses through chromatin-level mechanisms. While butyrate does not directly function as an AhR ligand, it appears capable of enhancing receptor activity in the presence of endogenous tryptophan-derived agonists by inhibiting HDAC at AhR target gene promoters (Modoux et al., 2022). Chromatin immunoprecipitation analyses in human intestinal explants have suggested that HDAC inhibition by butyrate may facilitate increased recruitment of AhR to responsive genomic regions, thereby amplifying transcriptional activation mediated by microbial indole compounds.

10 Peripheral immune imprinting and epigenetic reprogramming of microglia across the lifespan

Peripheral immune signals originating from infection, dysbiosis, or systemic inflammation are increasingly recognized as modulators of CNS immune homeostasis (Mou et al., 2022). In this context, microglia have gained attention as long-lived innate immune cells capable of integrating prior environmental exposures into altered functional phenotypes over extended temporal scales. This adaptive capacity, often conceptualized as innate immune memory, is thought to arise not from permanent genetic alteration but from dynamic reconfiguration of chromatin architecture that regulates stimulus-dependent transcriptional programs (Tay et al., 2017; Haley et al., 2019). A summary of representative experimental studies investigating epigenetic mechanisms underlying microglial immune memory and inflammatory priming is provided in Table 7. At the mechanistic level, epigenetic restructuring of enhancer regions has been proposed as a central process through which innate immune cells acquire heightened or attenuated responsiveness following inflammatory exposure.

Table 7

Experimental modelImmune trigger/stimulusEpigenetic or regulatory mechanismNeuroimmune/biological outcomeConceptual implicationRef
Primary microglia, PD mouse model, postmortem human PD brainLPS priming followed by manganese (Mn) stressEnhanced deposition of H3K27ac, H3K4me3, H3K4me1Exaggerated inflammatory cytokine responses in primed microgliaEpigenetic reprogramming mediates microglial immune memory(Huang et al., 2023)
Macrophage and B-cell lineage systemsLineage transcription factor cooperationPU.1-driven establishment of H3K4me1-marked enhancer regionsSpecification of cell-type gene regulatory programsLineage-determining TF networks prime immune enhancer landscapes(Heinz et al., 2010)
Embryonic stem cells and adult mouse tissuesDevelopmental transcriptional programsH3K27ac distinguishes active vs poised enhancersPrediction of enhancer activity and cellular stateHistone acetylation marks regulate enhancer activation states(Creyghton et al., 2010)
Dendritic cells analyzed by high−throughput ChIPPathogen stimulationDynamic transcription factor binding prior to gene activationPre-bound regulatory complexes enable rapid gene inductionImmune genes may be primed epigenetically before stimulation(Garber et al., 2012)
Activated macrophagesTLR4 signalingDe novo enhancer formation with H3K4 methylation and enhancer transcriptionActivation of inflammatory gene expression programsEnhancer remodeling coordinates macrophage immune activation(Kaikkonen et al., 2013)
Differentiated macrophagesEnvironmental immune stimulationFormation of latent enhancers acquiring TF binding and histone marksEnhanced transcriptional response upon restimulationLatent enhancer activation creates epigenomic memory(Ostuni et al., 2013)
Macrophage inflammatory gene networksEndotoxin stimulationPU.1−dependent enhancer activity with p300 acetyltransferase recruitmentRegulation of inflammatory transcription programsCombinatorial transcription factor networks regulate immune enhancers(Ghisletti et al., 2010)
Mouse microglia analyzed by ATAC−seq, ChIP−seq and RNA−seqRepeated LPS exposure or genotoxic stressGain or loss of permissive enhancer-associated chromatin marksPrimed or tolerized microglial phenotypesMicroglial innate immune memory linked to epigenetic enhancer remodeling(Zhang et al., 2022)
In vivo cortical microglia imagingBlood–brain barrier disruption or injuryActivity-dependent microglial activationRapid microglial surveillance and response to tissue damageMicroglia function as dynamic environmental immune sensors(Nimmerjahn et al., 2005)
Neonatal rat infection modelEarly bacterial infection followed by adult LPS challengePersistent neuroimmune sensitizationImpaired hippocampal-dependent contextual memoryEarly immune exposure predisposes to later cognitive vulnerability(Bilbo et al., 2006)
Fetal sheep microglia modelPrenatal LPS exposure followed by secondary stimulationAltered transcriptomic and HDAC-related pathwaysAmplified cytokine responses in primed microgliaPrenatal inflammation programs long-term microglial responses(Cao et al., 2015)
Young vs aged micePeripheral LPS challengeAge-associated amplification of inflammatory signalingProlonged sickness and depressive-like behaviorAging enhances brain sensitivity to peripheral immune activation(Godbout et al., 2008)
Isolated microglia from aged mouse brainPeripheral endotoxin exposureIncreased cytokine induction and immune receptor expressionHyper-responsive microglial inflammatory phenotypeAge-associated microglial priming contributes to neuroinflammation(Henry et al., 2009)
Mouse developmental inflammation modelNeonatal LPS exposure followed by adult challengeLong-term neuroimmune and HPA-axis alterationsImpaired spatial memory and altered emotional behaviorEarly-life inflammation induces lifelong neuroimmune vulnerability(Dinel et al., 2014)
Mouse model of systemic immune activation (PolyI:C)Prenatal and adult immune challengeChronic inflammatory signaling and APP dysregulationAlzheimer-like neuropathology during agingSystemic immune activation may initiate neurodegenerative pathology(Krstic et al., 2012)

Experimental and mechanistic evidence supporting peripheral immune imprinting and epigenetic reprogramming of microglia across the lifespan.

PD, Parkinson’s disease; TLR4, Toll-like receptor 4; LPS, lipopolysaccharide; HDAC, histone deacetylase; HPA axis, hypothalamic–pituitary–adrenal axis; ATAC-seq, assay for transposase-accessible chromatin sequencing; ChIP-seq, chromatin immunoprecipitation sequencing; RNA-seq, RNA sequencing.

In myeloid lineage cells, lineage-determining transcription factors such as PU.1 cooperate with signal-responsive transcription factors to establish accessible chromatin domains at distal regulatory loci marked by histone H3 lysine 4 monomethylation (H3K4me1), thereby facilitating nucleosome remodeling and priming inflammatory gene enhancers without necessarily initiating immediate transcriptional output (Ghisletti et al., 2010; Heinz et al., 2010). Consistent with this hierarchical framework, genome-scale chromatin immunoprecipitation studies have demonstrated that a substantial proportion of transcription factor–DNA interactions associated with inflammatory gene programs are already established prior to pathogen exposure (Garber et al., 2012). Such pre-bound complexes, frequently localized at immediate-early response elements, may act as transcriptional placeholders that enable rapid gene activation upon secondary environmental stimulation. Inflammatory engagement of pattern-recognition receptors, including Toll-like receptor 4 through bacterial LPS, has been shown to further remodel this enhancer landscape. Activation of macrophages is associated with the emergence of newly primed regulatory regions characterized by deposition of mono- and dimethylated H3K4 marks, processes that appear to involve histone methyltransferases of the MLL family (Kaikkonen et al., 2013). In certain contexts, transcription of enhancer-associated RNA precedes detectable histone methylation at these loci, suggesting that chromatin priming may be initiated prior to overt transcriptional changes in adjacent genes. Beyond inducible enhancer formation, differentiated innate immune cells may harbor previously unmarked genomic regions termed latent enhancers that acquire transcription factor occupancy and active histone modifications only following environmental stimulation (Ostuni et al., 2013).

Enhancer activity states may be further distinguished by histone acetylation marks such as H3K27ac, which are generally associated with transcriptionally engaged regulatory elements and have recently been implicated in the establishment of inflammatory memory and epigenetic priming in microglial cells following immune stimulation (Huang et al., 2023). Regions marked solely by H3K4me1 are often considered inactive or poised, whereas co-enrichment with H3K27ac reflects active participation in gene transcription programs (Creyghton et al., 2010). While many of these observations have been derived from peripheral macrophage models, emerging data suggest that comparable chromatin-level mechanisms may operate within microglia following systemic immune exposure. Microglial cells, as long-lived tissue-resident macrophages of the CNS, continuously survey their microenvironment even under homeostatic conditions through highly motile processes capable of rapidly responding to perturbations (Nimmerjahn et al., 2005). Experimental studies indicate that systemic inflammatory events occurring during sensitive developmental windows can exert lasting effects on microglial reactivity that remain functionally silent under basal conditions.

Neonatal exposure to peripheral bacterial infection has been associated with hippocampal-dependent memory impairments that become apparent only after a secondary immune challenge in adulthood (Bilbo et al., 2006). Similarly, postnatal inflammatory stimulation has been linked to alterations in emotional behaviour and impaired spatial memory following re-exposure to LPS later in life, despite minimal detectable deficits after the initial insult (Dinel et al., 2014). These findings suggest that early-life peripheral immune activation may induce a latent susceptibility state rather than immediate neuropathology. At the cellular level, this latent vulnerability appears to involve persistent transcriptional and epigenetic alterations in microglia following systemic inflammatory exposure. Models of fetal neuroinflammation have demonstrated that microglia isolated from in vivo LPS-exposed animals exhibit amplified cytokine responses upon subsequent in vitro stimulation, accompanied by differential regulation of inflammatory and metabolic pathways (Cao et al., 2015). Alterations in HDAC isoforms observed after repeated immune challenge further support the possibility that inflammatory memory in microglia may involve chromatin-level reprogramming rather than transient transcriptional activation alone (Cao et al., 2015). In agreement with this interpretation, genome-wide epigenomic profiling has shown that inflammatory priming is associated with enrichment of permissive epigenetic marks at enhancer regions, whereas tolerized responses may involve loss of such marks, collectively giving rise to distinct transcription factor networks and microglial phenotypes (Zhang et al., 2022). The functional consequences of such priming may become increasingly evident with advancing age. Aging has been associated with exaggerated neuroinflammatory responses to peripheral immune stimulation, including prolonged sickness behaviour and heightened induction of inflammatory mediators following systemic LPS administration (Godbout et al., 2008). Peripheral LPS challenge has also been shown to induce greater expression of cytokines such as interleukin-1β and interleukin-10, as well as increased major histocompatibility complex class II expression in microglia isolated from aged brains compared to younger counterparts (Henry et al., 2009). Beyond altered immune responsiveness, systemic immune challenges during sensitive developmental periods have been implicated in the initiation or acceleration of neuropathological processes later in life. Prenatal immune activation using viral mimetics has been shown to predispose mice to develop Alzheimer-like neuropathological features during aging, including increased amyloid precursor protein accumulation, altered tau phosphorylation, and sustained microglial activation (Krstic et al., 2012). When followed by a second immune challenge in adulthood, these alterations were further exacerbated, suggesting that repeated inflammatory events may interact to amplify neurodegenerative trajectories over time.

11 Conclusions and future perspectives

This review highlights growing evidence that infection-associated gut dysbiosis may contribute to long-term variability in neuroinflammatory susceptibility by influencing systemic immune homeostasis. A key mechanistic insight is that microbiota-derived metabolites, including SCFAs and tryptophan-derived indole compounds, may interact with host epigenetic machinery, thereby linking peripheral immune activity to sustained transcriptional regulation in innate immune cells. Microglia represent a central interface in this process due to their longevity and capacity for functional adaptation. Experimental studies suggest that early-life or repeated immune challenges may induce persistent changes in microglial responsiveness, potentially shaping later neuroinflammatory outcomes. However, current evidence remains largely derived from preclinical models and associative human studies, limiting causal interpretation. Future research should focus on longitudinal, multi-omics human studies integrating microbiome, immune, and brain readouts to establish causal relationships and identify modifiable neuroimmune pathways. Such approaches will be essential to determine whether microbiota-driven epigenetic and immune programming represents a targetable mechanism in NDDs.

Statements

Author contributions

DH: Supervision, Methodology, Investigation, Conceptualization, Writing – original draft, Writing – review & editing, Visualization, Validation, Data curation. CY: Visualization, Writing – original draft, Data curation, Investigation, Methodology, Conceptualization, Writing – review & editing, Validation.

Funding

The author(s) declared that financial support was not received for this work and/or its publication.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 1

    AbdelhamidM.JungC.-G.ZhouC.InoueR.ChenY.SentoY.et al. (2024). Potential therapeutic effects of bifidobacterium breve MCC1274 on Alzheimer’s disease pathologies in AppNL-GF mice. Nutrients16, 538. doi: 10.3390/nu16040538

  • 2

    Aboytes FloresP. (2023). BACTERIAL AMYLOID CURLI INFLUENCES AGGREGATION OF AMYLOID BETA PEPTIDES ASSOCIATED WITH ALZHEIMER ́S DISEASE: University of Saskatchewan. 2023, 1–116.

  • 3

    AgahiA.HamidiG. A.DaneshvarR.HamdiehM.SoheiliM.AlinaghipourA.et al. (2018). Does severity of Alzheimer's disease contribute to its responsiveness to modifying gut microbiota? A double blind clinical trial. Front. Neurol.9, 662. doi: 10.3389/fneur.2018.00662

  • 4

    Ahmed Abdellatif AbdelhamidM. (2023). Probiotic Bifidobacterium breve MCC1274 mitigates Alzheimer's disease-related pathologies in wild-type mice. 14 (12), 2543. doi: 10.3390/nu14122543

  • 5

    AliS. A.ChungK. H. K.ForghamH.OlsenW. P.KakinenA.BalajiA.et al. (2023). Alzheimer's progenitor amyloid‐β targets and dissolves microbial amyloids and impairs biofilm function. Adv. Sci.10, 2301423. doi: 10.1002/advs.202301423

  • 6

    AsadifardE.HokmabadiM.HashemiM.BereimipourA. (2024). Linking gut microbiota dysbiosis to molecular pathways in Alzheimer’s disease. Brain Res.1845, 149242. doi: 10.1016/j.brainres.2024.149242

  • 7

    AslZ. R.SepehriG.SalamiM. (2019). Probiotic treatment improves the impaired spatial cognitive performance and restores synaptic plasticity in an animal model of Alzheimer's disease. Behav. Brain Res.376, 112183. doi: 10.1016/j.bbr.2019.112183

  • 8

    AssimakopoulosS. F.MastronikolisS.De LasticA.-L.ArethaD.PapageorgiouD.ChalkidiT.et al. (2021). Intestinal barrier biomarker ZO1 and endotoxin are increased in blood of patients with COVID-19-associated pneumonia. In Vivo35, 2483–2488. doi: 10.21873/invivo.12528

  • 9

    AungH. T.SchroderK.HimesS. R.BrionK.Van ZuylenW.TrieuA.et al. (2006). LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression. FASEB J.20, 1315–1327. doi: 10.1096/fj.05-5360com

  • 10

    BenMarzouk-HidalgoO. J.Torres-CornejoA.Gutierrez-ValenciaA.Ruiz-ValderasR.VicianaP.Lopez-CortesL. F. (2015). Differential effects of viremia and microbial translocation on immune activation in HIV-infected patients throughout ritonavir-boosted darunavir monotherapy. Medicine94, e781. doi: 10.1097/md.0000000000000781

  • 11

    Berni CananiR.Di CostanzoM.LeoneL. (2012). The epigenetic effects of butyrate: potential therapeutic implications for clinical practice. Clin. Epigenet.4, 1–7. doi: 10.1186/1868-7083-4-4

  • 12

    BilboS. D.RudyJ. W.WatkinsL. R.MaierS. F. (2006). A behavioural characterization of neonatal infection-facilitated memory impairment in adult rats. Behav. Brain Res.169, 39–47. doi: 10.1016/j.bbr.2005.12.002

  • 13

    BureI. V.NemtsovaM. V.KuznetsovaE. B. (2022). Histone modifications and non-coding RNAs: mutual epigenetic regulation and role in pathogenesis. Int. J. Mol. Sci.23, 5801. doi: 10.3390/ijms23105801

  • 14

    CannonJ. R.GreenamyreJ. T. (2011). The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol. Sci.124, 225–250. doi: 10.1093/toxsci/kfr239

  • 15

    CaoM.CortesM.MooreC. S.LeongS. Y.DurosierL. D.BurnsP.et al. (2015). Fetal microglial phenotype in vitro carries memory of prior in vivo exposure to inflammation. Front. Cell. Neurosci.9, 294. doi: 10.3389/fncel.2015.00294

  • 16

    CaradonnaE.NemniR.BifoneA.GandolfoP.CostantinoL.GiordanoL.et al. (2024). The brain–gut axis, an important player in alzheimer and parkinson disease: a narrative review. J. Clin. Med.13, 4130. doi: 10.3390/jcm13144130

  • 17

    CarlessiA. S.BorbaL. A.ZugnoA. I.QuevedoJ.RéusG. Z. (2021). Gut microbiota–brain axis in depression: The role of neuroinflammation. Eur. J. Neurosci.53, 222–235. doi: 10.1111/ejn.14631

  • 18

    ChancharoenthanaW.KamolratanakulS.AriyanonW.ThanachartwetV.PhumratanaprapinW.WilairatanaP.et al. (2022). Abnormal blood bacteriome, gut dysbiosis, and progression to severe dengue disease. Front. Cell. Infect. Microbiol.12, 890817. doi: 10.3389/fcimb.2022.890817

  • 19

    ChandraR.HinikerA.KuoY.-M.NussbaumR. L.LiddleR. A. (2017). α-Synuclein in gut endocrine cells and its implications for Parkinson’s disease. JCI Insight2, e92295. doi: 10.1172/jci.insight.92295

  • 20

    ChangP. V.HaoL.OffermannsS.MedzhitovR. (2014). The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc. Natl. Acad. Sci.111, 2247–2252. doi: 10.1073/pnas.1322269111

  • 21

    ChenD.YangX.YangJ.LaiG.YongT.TangX.et al. (2017). Prebiotic effect of fructooligosaccharides from Morinda officinalis on Alzheimer’s disease in rodent models by targeting the microbiota-gut-brain axis. Front. Aging Neurosci.9, 403. doi: 10.3389/fnagi.2017.00403

  • 22

    ChriettS.DąbekA.WojtalaM.VidalH.BalcerczykA.PirolaL. (2019). Prominent action of butyrate over β-hydroxybutyrate as histone deacetylase inhibitor, transcriptional modulator and anti-inflammatory molecule. Sci. Rep.9, 742. doi: 10.1038/s41598-018-36941-9

  • 23

    ChuyueD. Y.XuQ. J.ChangR. B. (2020). Vagal sensory neurons and gut-brain signaling. Curr. Opin. Neurobiol.62, 133–140. doi: 10.1016/j.conb.2020.03.006

  • 24

    CreyghtonM. P.ChengA. W.WelsteadG. G.KooistraT.CareyB. W.SteineE. J.et al. (2010). Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl. Acad. Sci.107, 21931–21936. doi: 10.1073/pnas.1016071107

  • 25

    CryanJ. F.O'RiordanK. J.CowanC. S.SandhuK. V.BastiaanssenT. F.BoehmeM.et al. (2019). The microbiota-gut-brain axis. Physiol. Rev.99, 1877–2013. doi: 10.1177/0706743716635538

  • 26

    DeelchandD. K.ShestovA. A.KoskiD. M.UğurbilK.HenryP. G. (2009). Acetate transport and utilization in the rat brain. J. Neurochem.109, 46–54. doi: 10.1111/j.1471-4159.2009.05895.x

  • 27

    DinelA.-L.JoffreC.TrifilieffP.AubertA.FouryA.Le RuyetP.et al. (2014). Inflammation early in life is a vulnerability factor for emotional behavior at adolescence and for lipopolysaccharide-induced spatial memory and neurogenesis alteration at adulthood. J. Neuroinflamm.11, 155. doi: 10.1186/s12974-014-0155-x

  • 28

    DongY.CuiC. (2022). The role of short-chain fatty acids in central nervous system diseases. Mol. Cell. Biochem.477, 2595–2607. doi: 10.1007/s11010-022-04471-8

  • 29

    DongX.YangT.JinZ. (2025). Lactobacillus reuteri-derived γ-amino butyric acid alleviates MPTP-induced Parkinson’s disease through inhibiting ferroptosis via the AKT-GSK3β-GPX4 axis. NPJ Parkinson's Dis.11, 149. doi: 10.1038/s41531-025-01022-y

  • 30

    DragoL.ValentinaC.FabioP. (2019). Gut microbiota, dysbiosis and colon lavage. Digestive Liver Dis.51, 1209–1213. doi: 10.1016/j.dld.2019.06.012

  • 31

    DuX.HuoX.YangY.HuZ.BotchwayB. O.JiangY.et al. (2017). MiR-124 downregulates BACE 1 and alters autophagy in APP/PS1 transgenic mice. Toxicol. Lett.280, 195–205. doi: 10.1016/j.toxlet.2017.08.082

  • 32

    ElangovanA.VenkatesanD.SelvarajP.PashaM. Y.BabuH. W. S.IyerM.et al. (2023). Mirna in Parkinson's disease: From pathogenesis to theranostic approaches. J. Cell. Physiol.238, 329–354. doi: 10.1002/jcp.30932

  • 33

    FarziA.FröhlichE. E.HolzerP. (2018). Gut microbiota and the neuroendocrine system. Neurotherapeutics15, 5–22. doi: 10.1007/s13311-017-0600-5

  • 34

    Fernández‐RuizJ. (2019). The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid‐based therapies to improve on the poor current therapeutic outcomes. Br. J. Pharmacol.176, 1370–1383. doi: 10.1111/bph.14382

  • 35

    FilipponeA. (2021). Modulation of Inflammation, Oxidative stress and Neuroinflammation by a short chain fatty acid: protective effects of sodium propionate in in vitro and in vivo studies.

  • 36

    ForsytheP.BienenstockJ.KunzeW. A. (2014). “ Vagal pathways for microbiome-brain-gut axis communication,” in Microbial Endocrinology: The Microbiota-Gut-Brain Axis in Health and Disease (New York, NY: Springer), 115–133.

  • 37

    FungT. C.OlsonC. A.HsiaoE. Y. (2017). Interactions between the microbiota, immune and nervous systems in health and disease. Nat. Neurosci.20, 145–155. doi: 10.1038/nn.4476

  • 38

    GarberM.YosefN.GorenA.RaychowdhuryR.ThielkeA.GuttmanM.et al. (2012). A high-throughput chromatin immunoprecipitation approach reveals principles of dynamic gene regulation in mammals. Mol. Cell47, 810–822. doi: 10.1016/j.molcel.2012.07.030

  • 39

    GhislettiS.BarozziI.MiettonF.PollettiS.De SantaF.VenturiniE.et al. (2010). Identification and characterization of enhancers controlling the inflammatory gene expression program in macrophages. Immunity32, 317–328. doi: 10.1016/j.immuni.2010.02.008

  • 40

    GodboutJ. P.MoreauM.LestageJ.ChenJ.SparkmanN. L.ConnorJ. O.et al. (2008). Aging exacerbates depressive-like behavior in mice in response to activation of the peripheral innate immune system. Neuropsychopharmacology33, 2341–2351. doi: 10.1016/j.bbi.2006.04.046

  • 41

    GräffJ.KimD.DobbinM. M.TsaiL.-H. (2011). Epigenetic regulation of gene expression in physiological and pathological brain processes. Physiol. Rev.91, 603–649. doi: 10.1152/physrev.00012.2010

  • 42

    GuiY.LiuH.ZhangL.LvW.HuX. (2015). Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget6, 37043–37053. doi: 10.18632/oncotarget.6158

  • 43

    HaaseS.WilckN.HaghikiaA.GoldR.MuellerD. N.LinkerR. A. (2020). The role of the gut microbiota and microbial metabolites in neuroinflammation. Eur. J. Immunol.50, 1863–1870. doi: 10.1002/eji.201847807

  • 44

    HalderR.HennionM.VidalR. O.ShomroniO.RahmanR.-U.RajputA.et al. (2016). DNA methylation changes in plasticity genes accompany the formation and maintenance of memory. Nat. Neurosci.19, 102–110. doi: 10.1038/nn.4194

  • 45

    HaleyM. J.BroughD.QuintinJ.AllanS. M. (2019). Microglial priming as trained immunity in the brain. Neuroscience405, 47–54. doi: 10.1016/j.neuroscience.2017.12.039

  • 46

    HarachT.MarungruangN.DuthilleulN.CheathamV.Mc CoyK.FrisoniG.et al. (2017). Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. Sci. Rep.7, 41802. doi: 10.1038/srep41802

  • 47

    HasegawaS.KumeH.IinumaS.YamasakiM.TakahashiN.FukuiT. (2012). Acetoacetyl-CoA synthetase is essential for normal neuronal development. Biochem. Biophys. Res. Commun.427, 398–403. doi: 10.1016/j.bbrc.2012.09.076

  • 48

    HeJ.JinY.HeC.LiZ.YuW.ZhouJ.et al. (2024). Danggui Shaoyao San: Comprehensive modulation of the microbiota-gut-brain axis for attenuating Alzheimer’s disease-related pathology. Front. Pharmacol.14, 1338804. doi: 10.3389/fphar.2023.1338804

  • 49

    HeJ.ZhangP.ShenL.NiuL.TanY.ChenL.et al. (2020). Short-chain fatty acids and their association with signalling pathways in inflammation, glucose and lipid metabolism. Int. J. Mol. Sci.21, 6356. doi: 10.3390/ijms21176356

  • 50

    HeL.ZhaoC.ZhangQ.ZintaG.WangD.Lozano-DuránR.et al. (2021). Pathway conversion enables a double-lock mechanism to maintain DNA methylation and genome stability. Proc. Natl. Acad. Sci.118, e2107320118. doi: 10.1073/pnas.2107320118

  • 51

    HeinzS.BennerC.SpannN.BertolinoE.LinY. C.LasloP.et al. (2010). Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell38, 576–589. doi: 10.1016/j.molcel.2010.05.004

  • 52

    HenryC. J.HuangY.WynneA. M.GodboutJ. P. (2009). Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1β and anti-inflammatory IL-10 cytokines. Brain Behavior Immun.23, 309–317. doi: 10.1016/j.bbi.2008.09.002

  • 53

    HombachS.KretzM. (2016). “ Non-coding RNAs: classification, biology and functioning,” in Non-Coding Rnas in Colorectal Cancer (Cham: Springer), 3–17.

  • 54

    HsuY.-C.HuangY.-Y.TsaiS.-Y.KuoY.-W.LinJ.-H.HoH.-H.et al. (2023). Efficacy of probiotic supplements on brain-derived neurotrophic factor, inflammatory biomarkers, oxidative stress and cognitive function in patients with Alzheimer’s dementia: A 12-week randomized, double-blind active-controlled study. Nutrients16, 16. doi: 10.3390/nu16010016

  • 55

    HuF.GaoQ.ZhengC.ZhangW.YangZ.WangS.et al. (2024). Encapsulated lactiplantibacillus plantarum improves Alzheimer’s symptoms in APP/PS1 mice. J. Nanobiotechnol.22, 582. doi: 10.1186/s12951-024-02862-1

  • 56

    HuM.ShaoZ. (2022). Lactobacillus pentosus alleviates lipopolysaccharide‐induced neuronal pyroptosis via promoting BIRC3‐mediated inactivation of NLRC4. Evidence‐Based Complementary Altern. Med.2022, 2124876. doi: 10.1155/2022/2124876

  • 57

    HuangH.-J.ChenJ.-L.LiaoJ.-F.ChenY.-H.ChieuM.-W.KeY.-Y.et al. (2021). Lactobacillus plantarum PS128 prevents cognitive dysfunction in Alzheimer’s disease mice by modulating propionic acid levels, glycogen synthase kinase 3 beta activity, and gliosis. BMC Complementary Med. Ther.21, 1–16. doi: 10.1186/s12906-021-03426-8

  • 58

    HuangM.MalovicE.EalyA.JinH.AnantharamV.KanthasamyA.et al. (2023). Microglial immune regulation by epigenetic reprogramming through histone H3K27 acetylation in neuroinflammation. Front. Immunol.14, 1052925. doi: 10.3389/fimmu.2023.1052925

  • 59

    HutchinsonN. T.WangS. S.RundL. A.Caetano-SilvaM. E.AllenJ. M.JohnsonR. W.et al. (2023). Effects of an inulin fiber diet on the gut microbiome, colon, and inflammatory biomarkers in aged mice. Exp. Gerontology176, 112164. doi: 10.1016/j.exger.2023.112164

  • 60

    HuuskonenJ.SuuronenT.NuutinenT.KyrylenkoS.SalminenA. (2004). Regulation of microglial inflammatory response by sodium butyrate and short-chain fatty acids. Br. J. Pharmacol.141, 874–880. doi: 10.1038/sj.bjp.0705682

  • 61

    IlottN. E.BollrathJ.DanneC.SchieringC.ShaleM.AdelmannK.et al. (2016). Defining the microbial transcriptional response to colitis through integrated host and microbiome profiling. ISME J.10, 2389–2404. doi: 10.1038/ismej.2016.40

  • 62

    IshiiT.FuruokaH.KayaM.KuharaT. (2021). Oral administration of probiotic Bifidobacterium breve improves facilitation of hippocampal memory extinction via restoration of aberrant higher induction of neuropsin in an MPTP-induced mouse model of Parkinson’s disease. Biomedicines9, 167. doi: 10.3390/biomedicines9020167

  • 63

    IsslerO.ChenA. (2015). Determining the role of microRNAs in psychiatric disorders. Nat. Rev. Neurosci.16, 201–212. doi: 10.1038/nrn3879

  • 64

    JakovcevskiM.AkbarianS. (2012). Epigenetic mechanisms in neurological disease. Nat. Med.18, 1194–1204. doi: 10.1038/nm.2828

  • 65

    JiangM.JiangQ.WuH.DuanX.ZhangF.MaH.et al. (2025). Butyrate ameliorates lung inflammation in chronic obstructive pulmonary disease in association with the regulation of histone lactylation: A mechanistic study. Life Sci., 124170. doi: 10.1016/j.lfs.2025.124170

  • 66

    JiangL.WangJ.LiuZ.JiangA.LiS.WuD.et al. (2020). Sodium butyrate alleviates lipopolysaccharide-induced inflammatory responses by down-regulation of NF-κB, NLRP3 signaling pathway, and activating histone acetylation in bovine macrophages. Front. Vet. Sci.7, 579674. doi: 10.3389/fvets.2020.579674

  • 67

    KaikkonenM. U.SpannN. J.HeinzS.RomanoskiC. E.AllisonK. A.StenderJ. D.et al. (2013). Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. Mol. Cell51, 310–325. doi: 10.1016/j.molcel.2013.07.010

  • 68

    KaurR.BaldiA.BaldiA. (2025). Artificial intelligence in herbal drug authentication: Revolutionizing identification, adulterant detection and standardization. Curr. Comput. Sci.4, E29503779378012. doi: 10.2174/0129503779378012250613194901

  • 69

    KaurH.GolovkoS.GolovkoM. Y.SinghS.DarlandD. C.CombsC. K. (2020). Effects of probiotic supplementation on short chain fatty acids in the App NL-GF mouse model of Alzheimer’s disease. J. Alzheimer's Dis.76, 1083–1102. doi: 10.3233/aiad220028

  • 70

    KhanS.JenaG. (2015). The role of butyrate, a histone deacetylase inhibitor in diabetes mellitus: Experimental evidence for therapeutic intervention. Epigenomics7, 669–680. doi: 10.2217/epi.15.20

  • 71

    KlausD. A.MotalM. C.Burger-KleppU.MarschalekC.SchmidtE. M.Lebherz-EichingerD.et al. (2013). Increased plasma zonulin in patients with sepsis. Biochem. Med.23, 107–111. doi: 10.11613/bm.2013.013

  • 72

    KourtisA. P.IbegbuC. C.WienerJ.KingC. C.TeghaG.KamwendoD.et al. (2013). Role of intestinal mucosal integrity in HIV transmission to infants through breast-feeding: The BAN study. J. Infect. Dis.208, 653–661. doi: 10.1093/infdis/jit221

  • 73

    KrsticD.MadhuSudanA.DoehnerJ.VogelP.NotterT.ImhofC.et al. (2012). Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J. Neuroinflamm.9, 151. doi: 10.1186/1742-2094-9-151

  • 74

    LeeY. Z.ChengS.-H.ChangM.-Y.LinY.-F.WuC.-C.TsaiY.-C. (2023). Neuroprotective effects of lactobacillus plantarum PS128 in a mouse model of parkinson’s disease: The role of gut microbiota and microRNAs. Int. J. Mol. Sci.24, 6794. doi: 10.3390/ijms24076794

  • 75

    LeeC. Y.RyuI. S.RyuJ.-H.ChoH.-J. (2021). MiRNAs as therapeutic tools in Alzheimer’s disease. Int. J. Mol. Sci.22, 13012. doi: 10.3390/ijms222313012

  • 76

    LeviM.KellerT. T.van GorpE.ten CateH. (2003). Infection and inflammation and the coagulation system. Cardiovasc. Res.60, 26–39. doi: 10.1016/s0008-6363(02)00857-x

  • 77

    LiT.ChuC.YuL.ZhaiQ.WangS.ZhaoJ.et al. (2022). Neuroprotective effects of Bifidobacterium breve CCFM1067 in MPTP-induced mouse models of Parkinson’s disease. Nutrients14, 4678. doi: 10.3390/nu14214678

  • 78

    LiH.SunJ.WangF.DingG.ChenW.FangR.et al. (2016). Sodium butyrate exerts neuroprotective effects by restoring the blood-brain barrier in traumatic brain injury mice. Brain Res.1642, 70–78. doi: 10.1016/j.brainres.2016.03.031

  • 79

    LinK.LinW.GuoZ.ChenC.ChenL.CaiX. (2025). Plasma exosomal miRNA expression and gut microbiota dysbiosis are associated with cognitive impairment in Alzheimer's disease. Front. Neurosci.19, 1545690. doi: 10.3389/fnins.2025.1545690

  • 80

    LiuY.ChengX.LiH.HuiS.ZhangZ.XiaoY.et al. (2022). Non-coding RNAs as novel regulators of neuroinflammation in Alzheimer’s disease. Front. Immunol.13, 908076. doi: 10.3389/fimmu.2022.908076

  • 81

    MartinelliA. H.LopesF. C.JohnE. B.CarliniC. R.Ligabue-BraunR. (2019). Modulation of disordered proteins with a focus on neurodegenerative diseases and other pathologies. Int. J. Mol. Sci.20, 1322. doi: 10.3390/ijms20061322

  • 82

    MastroeniD.GroverA.DelvauxE.WhitesideC.ColemanP. D.RogersJ. (2011). Epigenetic mechanisms in Alzheimer's disease. Neurobiol. Aging32, 1161–1182. doi: 10.1016/j.neurobiolaging.2010.08.017

  • 83

    MazzioE. A.SolimanK. F. (2012). Basic concepts of epigenetics: impact of environmental signals on gene expression. Epigenetics7, 119–130. doi: 10.4161/epi.7.2.18764

  • 84

    Miro-BlanchJ.YanesO. (2019). Epigenetic regulation at the interplay between gut microbiota and host metabolism. Front. Genet.10, 638. doi: 10.3389/fgene.2019.00638

  • 85

    MirzaeiV.EidiA.ManahejiH.OryanS.ZaringhalamJ. (2022). β-Hydroxybutyrate diminishes the apoptotic cell death and demyelination via altering bax, Caspase-3, and Bcl2 levels in the spinal cord of mice with MOG-induced encephalomyelitis. Neurochem. J.16, 322–333. doi: 10.1134/s1819712422030072

  • 86

    ModouxM.RolhionN.LefevreJ. H.OeuvrayC.NádvorníkP.IllesP.et al. (2022). Butyrate acts through HDAC inhibition to enhance aryl hydrocarbon receptor activation by gut microbiota-derived ligands. Gut Microbes14, 2105637. doi: 10.1080/19490976.2022.2105637

  • 87

    MoraisL. H.SchreiberI. H.MazmanianS. K. (2021). The gut microbiota–brain axis in behaviour and brain disorders. Nat. Rev. Microbiol.19, 241–255. doi: 10.1038/s41579-020-00460-0

  • 88

    MouY.DuY.ZhouL.YueJ.HuX.LiuY.et al. (2022). Gut microbiota interact with the brain through systemic chronic inflammation: Implications on neuroinflammation, neurodegeneration, and aging. Front. Immunol.13, 796288. doi: 10.3389/fimmu.2022.796288

  • 89

    MuthyalaS. D. V.ShankarS.KlemashevichC.BlazierJ. C.HillhouseA.WuC.-S. (2022). Differential effects of the soluble fiber inulin in reducing adiposity and altering gut microbiome in aging mice. J. Nutr. Biochem.105, 108999. doi: 10.1016/j.jnutbio.2022.108999

  • 90

    NimmerjahnA.KirchhoffF.HelmchenF. (2005). Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science308, 1314–1318. doi: 10.1515/nf-2005-0304

  • 91

    NshanianM.GruberJ. J.GellerB. S.ChleilatF.LancasterS. M.WhiteS. M.et al. (2025). Short-chain fatty acid metabolites propionate and butyrate are unique epigenetic regulatory elements linking diet, metabolism and gene expression. Nat. Metab.7 (1), 196–211. doi: 10.1038/s42255-024-01191-9

  • 92

    OstuniR.PiccoloV.BarozziI.PollettiS.TermaniniA.BonifacioS.et al. (2013). Latent enhancers activated by stimulation in differentiated cells. Cell152, 157–171. doi: 10.1016/j.cell.2012.12.018

  • 93

    PapasavvasE.AzzoniL.FoulkesA.ViolariA.CottonM. F.PistilliM.et al. (2011). Increased microbial translocation in≤ 180 days old perinatally human immunodeficiency virus-positive infants as compared with human immunodeficiency virus-exposed uninfected infants of similar age. Pediatr. Infect. Dis. J.30, 877–882. doi: 10.1097/inf.0b013e31821d141e

  • 94

    Parada‐VenegasD.De la Fuente LópezM.Dubois‐CamachoK.LandskronG.BlokzijlT.MolinaH.et al. (2025). Butyrate suppresses mucosal inflammation in inflammatory bowel disease primarily through HDAC3 inhibition in monocytes and macrophages. FEBS J.292, 6134–6157. doi: 10.1111/febs.70289

  • 95

    ParkJ. M.LeeS. C.HamC.KimY. W. (2023). Effect of probiotic supplementation on gastrointestinal motility, inflammation, motor, non-motor symptoms and mental health in Parkinson’s disease: A meta-analysis of randomized controlled trials. Gut Pathog.15, 9. doi: 10.1186/s13099-023-00536-1

  • 96

    PasupalakJ. K.RajputP.GuptaG. L. (2024). Gut microbiota and Alzheimer's disease: Exploring natural product intervention and the gut–brain axis for therapeutic strategies. Eur. J. Pharmacol., 177022. doi: 10.1016/j.ejphar.2024.177022

  • 97

    PatnalaR.ArumugamT. V.GuptaN.DheenS. T. (2017). HDAC inhibitor sodium butyrate-mediated epigenetic regulation enhances neuroprotective function of microglia during ischemic stroke. Mol. Neurobiol.54, 6391–6411. doi: 10.1007/s12035-016-0149-z

  • 98

    PedersenS. S.IngerslevL. R.OlsenM.PrauseM.BillestrupN. (2024). Butyrate functions as a histone deacetylase inhibitor to protect pancreatic beta cells from IL‐1β‐induced dysfunction. FEBS J.291, 566–583. doi: 10.1111/febs.17005

  • 99

    PetrovV.SaltykovaI.ZhukovaI.AlifirovaV.ZhukovaN.DorofeevaY. B.et al. (2017). Analysis of gut microbiota in patients with Parkinson’s disease. Bull. Exp. Biol. Med.162, 734–737. doi: 10.1007/s10517-017-3700-7

  • 100

    PietrucciD.CerroniR.UnidaV.FarcomeniA.PierantozziM.MercuriN. B.et al. (2019). Dysbiosis of gut microbiota in a selected population of Parkinson's patients. Parkinsonism Related Disord.65, 124–130. doi: 10.1016/j.parkreldis.2019.06.003

  • 101

    PolatK.GömleksizM.OralK.GözelN.SołowskiG.KaymazT.et al. (2024). Correlation of triethylamine N-oxide (TMAO), LPS, and TNF-Alpha levels with clinical features of the disease in patients with and without septic shock infected with COVID-19 virus. Clin. Ther.46, e1–e8. doi: 10.1016/j.clinthera.2024.09.021

  • 102

    PrasadR.PattonM. J.FloydJ. L.FortmannS.DuPontM.HarbourA.et al. (2022). Plasma microbiome in COVID-19 subjects: An indicator of gut barrier defects and dysbiosis. Int. J. Mol. Sci.23, 9141. doi: 10.3390/ijms23169141

  • 103

    RuschJ. A.LaydenB. T.DugasL. R. (2023). Signalling cognition: The gut microbiota and hypothalamic-pituitary-adrenal axis. Front. Endocrinol.14, 1130689. doi: 10.3389/fendo.2023.1130689

  • 104

    RutschA.KantsjöJ. B.RonchiF. (2020). The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology. Front. Immunol.11, 604179. doi: 10.3389/fimmu.2020.604179

  • 105

    SampsonT. R.ChallisC.JainN.MoiseyenkoA.LadinskyM. S.ShastriG. G.et al. (2020). A gut bacterial amyloid promotes α-synuclein aggregation and motor impairment in mice. elife9, e53111. doi: 10.7554/elife.53111

  • 106

    Santos-OliveiraJ. R.RegisE. G.Giacoia-GrippC. B.ValverdeJ. G.Alexandrino-de-OliveiraP.LindosoJ.Â.L.et al. (2013). Microbial translocation induces an intense proinflammatory response in patients with visceral leishmaniasis and HIV type 1 coinfection. J. Infect. Dis.208, 57–66. doi: 10.1093/infdis/jit135

  • 107

    SchultzeJ. (2017). Chromatin remodeling in monocyte and macrophage activation. Adv. Protein Chem. Struct. Biol.106, 1–15. doi: 10.1016/bs.apcsb.2016.09.001

  • 108

    ScottS. A.FuJ.ChangP. V. (2020). Microbial tryptophan metabolites regulate gut barrier function via the aryl hydrocarbon receptor. Proc. Natl. Acad. Sci.117, 19376–19387. doi: 10.1073/pnas.2000047117

  • 109

    SilvaL. G.FergusonB. S.AvilaA. S.FaciolaA. P. (2018). Sodium propionate and sodium butyrate effects on histone deacetylase (HDAC) activity, histone acetylation, and inflammatory gene expression in bovine mammary epithelial cells. J. Anim. Sci.96, 5244–5252. doi: 10.1093/jas/sky373

  • 110

    SongL.SunQ.ZhengH.ZhangY.WangY.LiuS.et al. (2022). Roseburia hominis alleviates neuroinflammation via short‐chain fatty acids through histone deacetylase inhibition. Mol. Nutr. Food. Res.66, 2200164. doi: 10.1002/mnfr.202200164

  • 111

    SouzaL. S.Ferreira-JuniorA. S.EstellaP. C.NodaR. K.SousaL. F.MurataM. T.et al. (2025). Bacteriome signature in SARS-CoV-2-infected patients correlates with increased gut permeability and systemic inflammatory cytokines. Microorganisms13, 1407. doi: 10.3390/microorganisms13061407

  • 112

    SteinR. A.RiberL. (2023). Epigenetic effects of short-chain fatty acids from the large intestine on host cells. Microlife4, uqad032. doi: 10.1093/femsml/uqad032

  • 113

    StillingR. M.van de WouwM.ClarkeG.StantonC.DinanT. G.CryanJ. F. (2016). The neuropharmacology of butyrate: The bread and butter of the microbiota-gut-brain axis? Neurochem. Int.99, 110–132. doi: 10.1016/j.neuint.2016.06.011

  • 114

    SunJ.LiH.JinY.YuJ.MaoS.SuK.-P.et al. (2021). Probiotic Clostridium butyricum ameliorated motor deficits in a mouse model of Parkinson’s disease via gut microbiota-GLP-1 pathway. Brain Behavior Immun.91, 703–715. doi: 10.1016/j.bbi.2020.10.014

  • 115

    SunJ.LiuS.LingZ.WangF.LingY.GongT.et al. (2019). Fructooligosaccharides ameliorating cognitive deficits and neurodegeneration in APP/PS1 transgenic mice through modulating gut microbiota. J. Agric. Food. Chem.67, 3006–3017. doi: 10.1021/acs.jafc.8b07313

  • 116

    SunJ.LuL.LianY.XuS.ZhuY.WuY.et al. (2025). Sodium butyrate attenuates microglia-mediated neuroinflammation by modulating the TLR4/MyD88/NF-κB pathway and microbiome-gut-brain axis in cardiac arrest mice. Mol. Brain.18, 1–23. doi: 10.1186/s13041-025-01179-w

  • 117

    SunJ.WangF.LiH.ZhangH.JinJ.ChenW.et al. (2015). Neuroprotective effect of sodium butyrate against cerebral ischemia/reperfusion injury in mice. BioMed. Res. Int.2015, 395895. doi: 10.1155/2015/395895

  • 118

    TanY.-Q.WangY.-N.FengH.-Y.GuoZ.-Y.LiX.NieX.-L.et al. (2022). Host/microbiota interactions-derived tryptophan metabolites modulate oxidative stress and inflammation via aryl hydrocarbon receptor signaling. Free Radical Biol. Med.184, 30–41. doi: 10.1016/j.freeradbiomed.2022.03.025

  • 119

    TayT. L.SavageJ. C.HuiC. W.BishtK.TremblayM. (2017). Microglia across the lifespan: From origin to function in brain development, plasticity and cognition. J. Physiol.595, 1929–1945. doi: 10.1113/jp272134

  • 120

    TorresB.GuardoA. C.LealL.LeonA.LuceroC.Alvarez‐MartinezM. J.et al. (2014). Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation. J. Int. AIDS Soc.17, 19246. doi: 10.7448/ias.17.1.19246

  • 121

    TsaoS.-P.YehT.-H.LinY.-T.PanC.-H.LeeY.-K.WuC.-H.et al. (2024). Supplementation with Bifidobacterium animalis subsp. lactis MH-022 for remission of motor impairments in a 6-OHDA-induced Parkinson's disease rat model by reducing inflammation, reshaping the gut microbiome, and fostering specific microbial taxa. Food. Funct.15, 9368–9389. doi: 10.1039/d4fo02039a

  • 122

    VallelungaA.RagusaM.Di MauroS.IannittiT.PilleriM.BiundoR.et al. (2014). Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and Multiple System Atrophy. Front. Cell. Neurosci.8, 156. doi: 10.3389/fncel.2014.00156

  • 123

    van de WouwM.BoehmeM.LyteJ. M.WileyN.StrainC.O'SullivanO.et al. (2018). Short-chain fatty acids: Microbial metabolites that alleviate stress-induced brain-gut axis alterations. J. Physiol.596, 4923–4944. doi: 10.1113/jp276431

  • 124

    VanuytselT.BercikP.BoeckxstaensG. (2023). Understanding neuroimmune interactions in disorders of gut–brain interaction: from functional to immune-mediated disorders. Gut72, 787–798. doi: 10.1136/gutjnl-2020-320633

  • 125

    VyhlídalováB.KrasulováK.PečinkováP.MarcalíkováA.VrzalR.ZemánkováL.et al. (2020). Gut microbial catabolites of tryptophan are ligands and agonists of the aryl hydrocarbon receptor: A detailed characterization. Int. J. Mol. Sci.21, 2614. doi: 10.3390/ijms21072614

  • 126

    WangH.HanJ.ZhangX.-A. (2025). Interplay of m6A RNA methylation and gut microbiota in modulating gut injury. Gut Microbes17, 2467213. doi: 10.1080/19490976.2025.2467213

  • 127

    WangF.LiuJ.WengT.ShenK.ChenZ.YuY.et al. (2017). The inflammation induced by lipopolysaccharide can be mitigated by short‐chain fatty acid, butyrate, through upregulation of IL‐10 in septic shock. Scand. J. Immunol.85, 258–263. doi: 10.1111/sji.12515

  • 128

    WangY.WangD.LvH.DongQ.LiJ.GengW.et al. (2022). Modulation of the gut microbiota and glycometabolism by a probiotic to alleviate amyloid accumulation and cognitive impairments in AD rats. Mol. Nutr. Food. Res.66, 2200265. doi: 10.1002/mnfr.202200265

  • 129

    WebberleyT. S.BevanR. J.Kerry-SmithJ.DallyJ.MichaelD. R.ThomasS.et al. (2023). Assessment of Lab4P probiotic effects on cognition in 3xTg-AD Alzheimer’s disease model mice and the SH-SY5Y neuronal cell line. Int. J. Mol. Sci.24, 4683. doi: 10.3390/ijms24054683

  • 130

    WebberleyT. S.MasettiG.BevanR. J.Kerry-SmithJ.JackA. A.MichaelD. R.et al. (2022). The impact of probiotic supplementation on cognitive, pathological and metabolic markers in a transgenic mouse model of Alzheimer’s disease. Front. Neurosci.16, 843105. doi: 10.3389/fnins.2022.843105

  • 131

    WeiH.HuY.YangL. (2021). Intestinal flora imbalance affects the prognosis of Parkinson's disease by regulating the expression of fecal microRNA-146a and GDNF: A preliminary study. Termedia Publi House15, 124–128. doi: 10.5114/aoms/143780

  • 132

    XiaoT.WuS.YanC.ZhaoC.JinH.YanN.et al. (2018). Butyrate upregulates the TLR4 expression and the phosphorylation of MAPKs and NK-κB in colon cancer cell in vitro. Oncol. Lett.16, 4439–4447. doi: 10.3892/ol.2018.9201

  • 133

    XuD.RenL.ZhangW.WuS.YuM.HeX.et al. (2024). Therapeutic effects and mechanisms of fecal microbiota transplantation on EAE partly through HPA axis-mediated neuroendocrine regulation. Heliyon10. doi: 10.1016/j.heliyon.2024.e33214

  • 134

    XuC.ZhuH.QiuP. (2019). Aging progression of human gut microbiota. BMC Microbiol.19, 1–10. doi: 10.1186/s12866-019-1616-2

  • 135

    YanM.LiX.SunC.TanJ.LiuY.LiM.et al. (2022). Sodium butyrate attenuates AGEs-induced oxidative stress and inflammation by inhibiting autophagy and affecting cellular metabolism in THP-1 cells. Molecules27, 8715. doi: 10.3390/molecules27248715

  • 136

    YangJ.MaloneF.GoM.KouJ.LimJ.-E.CaugheyR. C.et al. (2021). Lipopolysaccharide-induced exosomal miR-146a is involved in altered expression of Alzheimer’s risk genes via suppression of TLR4 signaling. J. Mol. Neurosci.71, 1245–1255. doi: 10.1007/s12031-020-01750-1

  • 137

    YeT.YuanS.KongY.YangH.WeiH.ZhangY.et al. (2022). Effect of probiotic fungi against cognitive impairment in mice via regulation of the fungal microbiota–gut–brain axis. J. Agric. Food. Chem.70, 9026–9038. doi: 10.1021/acs.jafc.2c03142

  • 138

    YeohY. K.ZuoT.LuiG.-Y.ZhangF.LiuQ.LiA. Y.et al. (2021). Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut70, 698–706. doi: 10.1136/gutjnl-2020-323020

  • 139

    YoshidaK.MaekawaT.ZhuY.Renard-GuilletC.ChattonB.InoueK.et al. (2015). The transcription factor ATF7 mediates lipopolysaccharide-induced epigenetic changes in macrophages involved in innate immunological memory. Nat. Immunol.16, 1034–1043. doi: 10.1038/ni.3257

  • 140

    YuN.-K.BaekS. H.KaangB.-K. (2011). DNA methylation-mediated control of learning and memory. Mol. Brain.4, 1–9. doi: 10.1186/1756-6606-4-5

  • 141

    ZhangQ.CaoX. (2021). Epigenetic remodeling in innate immunity and inflammation. Annu. Rev. Immunol.39, 279–311. doi: 10.1146/annurev-immunol-093019-123619

  • 142

    ZhangG.GhoshS. (2000a). Molecular mechanisms of NF-κB activation induced by bacterial lipopolysaccharide through Toll-like receptors. J. Endotoxin Res.6, 453–457. doi: 10.1177/09680519000060060701

  • 143

    ZhangG.GhoshS. (2000b). Molecular mechanisms of NF-kappaB activation induced by bacterial lipopolysaccharide through Toll-like receptors. J. Endotoxin Res.6, 453–457. doi: 10.1177/09680519000060060701

  • 144

    ZhangX.KrachtL.LerarioA. M.DubbelaarM. L.BrouwerN.WesselingE. M.et al. (2022). Epigenetic regulation of innate immune memory in microglia. J. Neuroinflamm.19, 111. doi: 10.1186/s12974-022-02463-5

  • 145

    ZhangJ. M.LiuX. Y.GuW.XuH. Y.JiaoH. C.ZhaoJ. P.et al. (2021). Different effects of probiotics and antibiotics on the composition of microbiota, SCFAs concentrations and FFAR2/3 mRNA expression in broiler chickens. J. Appl. Microbiol.131, 913–924. doi: 10.1111/jam.14953

  • 146

    ZhaoY.JaberV.LukiwW. J. (2021). Gastrointestinal tract microbiome-derived pro-inflammatory neurotoxins in Alzheimer’s disease. J. Aging Sci.9, 002. doi: 10.1186/s40168-021-01107-9

  • 147

    ZhaoZ.NingJ.BaoX.ShangM.MaJ.LiG.et al. (2021). Fecal microbiota transplantation protects rotenone-induced Parkinson’s disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis. Microbiome9, 1–27. doi: 10.1186/s40168-021-01107-9

  • 148

    ZhaoY.XuX.LiuS.WangX.MushaJ.LiT.et al. (2025). Butyrate inhibits histone deacetylase 2 expression to alleviate liver fibrosis in biliary atresia. BMC Pediatr.25, 286. doi: 10.1186/s12887-025-05635-3

  • 149

    ZhaoS.ZhongY.FuX.WangY.YeP.CaiJ.et al. (2019). H3K4 methylation regulates LPS-induced proinflammatory cytokine expression and release in macrophages. Shock51, 401–406. doi: 10.1097/shk.0000000000001141

  • 150

    ZhuG.ZhaoJ.ZhangH.ChenW.WangG. (2021). Administration of Bifidobacterium breve improves the brain function of Aβ1-42-treated mice via the modulation of the gut microbiome. Nutrients13, 1602. doi: 10.3390/nu13051602

Summary

Keywords

epigenetic reprogramming, infection-driven dysbiosis, neuroinflammation, probiotic, probiotic modulation

Citation

Han D and Yang C (2026) Infection-driven gut dysbiosis and epigenetic programming of microglia: toward a systems level framework linking microbial metabolites, neuroinflammation, synaptic dysfunction, and probiotic modulation. Front. Cell. Infect. Microbiol. 16:1815265. doi: 10.3389/fcimb.2026.1815265

Received

23 February 2026

Revised

03 June 2026

Accepted

22 June 2026

Published

24 July 2026

Volume

16 - 2026

Edited by

Benson Botchway, University of Nicosia, Cyprus

Reviewed by

Baby Chakrapani Pulikkaparambil Sasidharan, Cochin University of Science and Technology, India

Jazmin Meza Torres, University of Oxford, United Kingdom

Updates

Copyright

*Correspondence: Delin Han,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics